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Abstract 
 
Plant phenylpropanoid natural products are important in the discovery of safe and 
effective therapeutics.  Most plant natural products cannot be economically mass 
produced via extraction from plant tissue or chemical synthesis.  In recent decades, 
engineering microbes to carry out the biosynthesis of plant natural products has 
emerged as a powerful technology.  The goal of this thesis was to expand the 
capabilities of microbial biosynthesis of plant phenylpropanoids in Escherichia coli 
through exploring novel biosynthetic pathways and metabolic engineering tools.  I first 
explored the biosynthesis of valuable lignans in E. coli, establishing random oxidative 
radical coupling through overexpression of a laccase and attempting to show 
stereoselective coupling by a dirigent protein.  I also designed and built a biosynthetic 
pathway for rosmarinic acid, a valuable hydroxycinnamic acid ester, showed pathway 
bottlenecks and limitations, and identified future optimization strategies.  I have also 
begun a project to better understand cargo protein encapsulation within bacterial 
microcompartments and to develop their utility as a means of spatially organizing 
metabolic pathways.  This work has contributed significantly to the field of microbial 
metabolic engineering and has laid the groundwork for future economically viable 
production platforms. 
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Chapter 1. Bioactive Phenylpropanoids: Biosynthesis in Plants 
and Strategies for Microbial Production 
1. Background: the Need for Microbial Biosynthesis of Plant Natural Products 
Plants are the sources of myriad natural products which enhance the daily lives of 
human beings.  They have evolved the capability to synthesize these products for their 
own purposes – for protection from ultraviolet rays, to attract pollinators, and for defense 
against herbivores and pathogens.  Yet over the millennia humans have found their own 
uses these same compounds, as flavors and colors that please our senses, as 
components of our most nutritious foods, and as medicines to reduce pain, promote 
healing and treat disease.  Through the study of chemistry and biochemistry, humans 
have begun to understand on a molecular level the basis of the medicinal plants we 
have utilized for centuries, and much focus has been devoted to the discovery of 
valuable natural products for pharmaceutical use. 
 In recent decades, pharmaceutical discovery companies have shifted focus away 
from natural products due to limitations in their mass production.  Source plants are 
often slow-growing, producing little biomass and low concentrations of the valuable 
products; additionally, extraction of the desired compound is arduous, often requiring 
separation from hundreds of other compounds.[1-2]  Chemical synthesis provides a lower-
cost, more rapid means of producing pharmaceuticals; however, most known bioactive 
natural products are highly complex and contain multiple chiral centers, making their 
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chemical synthesis economically infeasible.[3]  Because of this, pharmaceutical 
companies have turned away from natural products and towards high-throughput 
screening of synthetic combinatorial chemical libraries for drug discovery.[4-5]  Strikingly, 
the value of natural products in pharma is illustrated by the fact that over half of the 
drugs approved and brought to market over the last three decades have been natural 
products, despite the shift towards synthetic drug discovery.[6]  In fact, the success rate 
for regulatory approval of drugs derived from natural products is fourfold greater than 
that of conventional synthetic drugs.[1]  It is becoming clear that easily-synthesized 
compounds cannot replace natural products in the discovery and implementation of new 
pharmaceuticals, which necessitates the development of an economical production 
platform for complex plant natural products. 
 With the advent of recombinant DNA technology, a new means of synthesizing 
complex natural products has emerged and shown high potential for economical 
production of valuable compounds.  After the discovery, cloning and characterization of 
genes and enzymes required for the biosynthesis of valuable compounds, microbes can 
be genetically reprogrammed to express non-native biosynthetic pathways and 
synthesize natural products through fermentation technology.  Microbial fermentations 
benefit from fast biomass generation, a simplified extraction process compared to plant 
tissue extraction, and the ability to generate valuable compounds from inexpensive 
feedstocks.[1]  The use of biosynthetic enzymes as in vivo catalysts makes this a stereo-
selective process, and the recent sequencing revolution has provided us with an 
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enormous number of potential biosynthetic enzymes.[7]  The implementation of this 
strategy has already led to the production of high value products in microbes, especially 
for plant-derived isoprenoids.  For example, the biosynthesis of artemisinic acid, an 
important precursor to the anti-malarial drug artemisinin, has been achieved in 
Saccharomyces cerevisiae to a titer of 25 g/L and has led to an economically viable 
semi-synthetic production platform for the drug.[8]  Likewise, key precursors to the anti-
cancer drug paclitaxel have been achieved on the g/L scale in engineered strains in 
Escherichia coli.[9]  Other medically-important plant isoprenoids, flavonoids, stilbenoids 
and alkaloids have also been produced in these hosts.[1, 10] 
 The goal of this thesis was to explore the microbial biosynthesis of plant-derived 
phenylpropanoid compounds with high medicinal value.  While the biosynthesis of some 
plant phenylpropanoids has already been achieved in microbes, they have mostly been 
limited to the hydroxycinnamic acid, flavonoid, and stilbenoid compounds, and have so 
far overlooked some key value-added compound classes.  Because of the previous 
success of the Schmidt-Dannert lab[11-12] and many other groups (reviewed in [1, 10]) in the 
use of E. coli as a host for flavonoid biosynthesis, I chose this highly-tractable 
microorganism as a host for phenylpropanoid biosynthetic pathways.  I first explored its 
potential as a host for the biosynthesis of lignans as a first step toward the microbial 
biosynthesis of podophyllotoxin, a highly cytotoxic pro-drug whose derivatives are widely 
used in chemotherapy.  I also developed a novel, chimeric biosynthetic pathway for an 
anti-cancer and neuroprotective hydroxycinnamic acid ester, rosmarinic acid, and 
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achieved its biosynthesis in E. coli for the first time.  Finally, I have attempted to optimize 
the rosmarinic acid biosynthetic pathway through co-localization of two key enzymes to 
engineered bacterial microcompartments (BMCs), and have investigated the mechanism 
of protein encapsulation within BMC shells.  This work has provided key insights into the 
biosynthesis of plant phenylpropanoids in E. coli, including its feasibility as a host for 
certain compound classes and the development of creative strategies to optimize and 
tailor pathways to the chosen host. 
2. Thesis Overview 
Chapter 1.  This chapter provides a background for the importance of plant 
phenylpropanoid compounds and their biosynthesis in E. coli.  I provide a summary of 
both plant and bacterial phenylpropanoid biosynthesis, and describe how groups have 
networked E. coli’s native L-tyrosine biosynthetic pathway with heterologous biosynthetic 
pathways to make value-added phenylpropanoids from simple feedstocks.  I also 
discuss the importance of spatial organization in metabolic pathways and outline 
recently-developed strategies for improving pathway flux through enzyme colocalization. 
 
Chapter 2.  This chapter describes my early work towards developing a lignan 
biosynthetic platform in E. coli.  Working in collaboration with Dr. Jacob Vick, I attempted 
the functional heterologous expression of two key proteins in the first committed step in 
lignan biosynthesis – a bacterial laccase and a plant-derived dirigent protein.  While I 
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achieved expression of both proteins, the dirigent protein was found to be non-functional 
in E. coli, calling into question the utility of this organism as a host for lignan 
biosynthesis. 
 
Chapter 3.  This chapter describes the design and construction of a hydroxycinnamic 
acid biosynthetic pathway in E. coli.  I conceptualized and implemented a chimeric 
biosynthetic pathway for rosmarinic acid distinct from that in plants, using both plant and 
bacterial enzymes.  While initial titers from the pathway are insufficient for an economical 
production platform, I provide several strategies for future pathway optimization based 
on my investigation of pathway bottlenecks and diversions. 
 
Chapter 4.  This chapter discusses an ongoing investigation in the Schmidt-Dannert 
laboratory into the mechanism of enzyme encapsulation into engineered Eut BMCs in E. 
coli.  I outline a strategy to optimize the rosmarinic acid biosynthetic pathway described 
in Chapter 3 through partial encapsulation within a BMC and show preliminary results of 
enzyme localization.  I also describe an investigation of the interactions between BMC 
shell and cargo proteins that mediate encapsulation and show evidence of cognate 
shell/cargo protein pairs.  For both of these studies, I propose future work to advance 
our understanding of enzyme encapsulation within BMCs.  While I conceptualized this 
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work, some of the cloning, mutagenesis and microscopy was carried out by Suzie Hsu 
and Dr. Mark Held. 
 
Chapter 5.  This chapter summarizes the work described in the previous chapters and 
highlights its contribution to the field of microbial metabolic engineering. 
 
3. Phenylpropanoid Biosynthesis in Plants and Bacteria 
The biosynthesis of bioactive plant phenylpropanoids begins with the generation of 
aromatic amino acids via the shikimate pathway (Scheme 1.1).[13]  The first step in 
shikimate biosynthesis is the condensation of phosphoenolpyruvate (PEP) from the 
glycolytic pathway and erythrose-4-phosphate (E4P) from the Calvin cycle and the 
pentose phosphate pathway to give 3-deoxy-D-arabinoheptulosonate-7-phosphate 
(DAHP) in a reaction catalyzed by DAHP synthase (DAHPS).  DAHP is then converted 
via three enzymatic steps into shikimate, which is the key starting point in the aromatic 
amino acid biosynthesis (AAAB) pathway.[14]  Another three enzymatic steps convert 
shikimate to chorismate, which is acted upon by chorismate mutase (CM) to produce 
prephenate.  Prephenate serves as the branch point for L-phenylalanine and L-tyrosine 
biosynthesis, with prephenate dehydratase (PDT) and phenylpyruvate aminotransferase 
catalyzing its conversion to L-phenylalanine, and prephanate dehydrogenase (PDH) and 
4-hydroxyphenylpyruvate aminotransferase catalyzing its conversion to L-tyrosine.[15]  
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 For the most part, E. coli shares the same biosynthetic pathway for the aromatic 
amino acids, except that chorismate serves as the branch point for L-phenylalanine and 
L-tyrosine biosynthesis.  Additionally, in E. coli, a single bi-functional enzyme, CM-PDT 
or CM-PDH, converts chorismate into either phenylpyruvate or 4-
hydroxyphenylpyruvate, respectively (Scheme 1.2).[16]  In plants, the activity of PDT and 
PDH is known to be subject to feedback inhibition by L-phenylalanine and L-tyrosine.[13, 
15]  Likewise, in E. coli, it has been shown that CM-PDT and CM-PDH are subject to 
feedback inhibition by L-phenylalanine and L-tyrosine, and that this is mediated by the 
PDH/PDT domain rather than the CM domain.[16-17]   
 The gateway from AAAB into bioactive phenylpropanoid biosynthesis is the 
generation of hydroxycinnamic acids.  In plants, this is primarily carried out by the 
conversion of L-phenylalanine to cinnamic acid catalyzed by a phenylalanine ammonia 
lyase (PAL), followed by the hydroxylation of cinnamate to give p-coumarate.  A few 
bacterial genomes contain genes encoding PALs and/or tyrosine ammonia lyases 
(TALs) and can therefore synthesize hydroxycinnamic acids and some further modified 
phenylpropanoid compounds (e.g. [18-20]).  All vascular plants, on the other hand, are able 
to synthesize a diverse array of compounds from the hydroxycinnamic acid precursor 
coumarate (Scheme 1.1).  Ortho-hydroxylated phenylpropanoids lead to the biosynthesis 
of the benzopyrone compounds known as coumarins, while para-hydroxylation of 
cinnamate to p-coumarate by a cinnamate-4-hydroxylase (C4H) and activation to p-
coumaroyl-CoA by a 4-coumarate-CoA ligase (4CL) leads to the majority of 
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Scheme 1.1. Overview of plant phenylpropanoid biosynthesis.  The key branch point 
leading to a wide array of plant phenylpropanoids, p-coumaroyl-CoA, is boxed.  Solid arrows 
represent key biosynthetic enzymes; dashed arrows represent several known or unknown 
enzymatic steps.  E4P, erythrose-4-phosphate; PEP, phosphoenolpyruvate; DAHP, 3-Deoxy-
D-arabinoheptulosonate 7-phosphate; DAHPS, DAHP synthase; CM, chorismate mutase; 
PDH, prephenate dehydrogenase; PDT, prephenate dehydratase; PAL, phenylalanine 
ammonia lyase; C4H, cinnamate 4-hydroxylase; 4CL, 4-coumaroyl-CoA ligase; HCT, 
hydroxycinnamoyl transferase; CHS, chalcone synthase; STS, stilbene synthase. 
 9 
 
characterized plant phenylpropanoids.[13]  Conjugation of p-coumarate to another 
aromatic molecule such as shikimate, quinate, or anthranilate by a hydroxycinnamoyl 
transferase results in the formation of hydroxycinnamic acid esters and amides, which 
make up the most abundant category of bioavailable hydroxycinamic acids in human 
foods.[21-23]  Addition of three malonyl-CoA units to p-coumarate by a type III polyketide 
synthase, such as chalcone synthase (CHS), leads to the biosynthesis of flavonoids and 
stilbenoids, a highly antioxidant group of compounds including tannins, anthocyanins, 
and aurones.[24]  In vascular plants, p-coumarate is further hydroxylated, methoxylated 
and reduced to give monolignols, the monomeric units of the vascular cell wall polymer 
lignin.[25]  Monolignols are oxidized by a single-electron oxidase and either undergo 
random radical coupling to form lignin[26] or regio- and stereo-selective coupling to give 
lignans, highly antioxidant and often cytotoxic compounds.[27]  Monolignols may also 
undergo acetylation and further reduction, generating volatile phenylpropenes such as 
eugenol and chavicol.[28-29]  From each of these major classes of compounds, valuable 
anti-oxidant, anti-inflammatory, anti-cancer, anti-bacterial, or otherwise useful 
compounds have been isolated and characterized. 
4.  Engineering Microbes for Plant Phenylpropanoid Biosynthesis 
4.1 General principles of microbial metabolic engineering 
Since its conception in the mid-1990s, metabolic engineering has emerged as a 
promising biotechnological means for the production of fuels, commodity chemicals and 
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high-value medicinal compounds.[30-31]  Microbial metabolic engineering of plant 
biosynthetic pathways involves five major considerations: choice of host, choice of 
feedstock, selection of enzymes, construction of expression vectors, and pathway 
optimization.  E. coli and S. cerevisiae are the two most commonly-used hosts, due to 
their genetic tractability and well-developed fermentation technology, and both have 
been used as hosts for plant natural product biosynthesis, including for 
phenylpropanoids.[32]  An attractive feature of microbial biosynthesis is the ability for 
microbes to turn inexpensive feedstocks into value-added products, and much success 
has come from the engineering of the mevalonate pathway in E. coli and S. cerevisiae to 
allow for production of medicinal isoprenoids from simple sugars.[33]  In some cases, 
however, the efficient conversion of sugars into natural product precursors has not been 
achieved, and feeding of inexpensive precursors downstream of the host’s central 
metabolism provides an alternative means of production.[32]  While the current 
sequencing revolution has caused the number of available enzymes for biosynthesis to 
skyrocket, care must be taken when selecting biocatalysts.  Certain enzymes can be 
problematic in microbes, especially plant enzymes.  For example, plant microsomal 
cytochrome P450s, which are key enzymes in the modification of bioactive products, 
require extensive expression optimization in microbial hosts.[34]  Drawing enzymes from 
microbial sources, as well as “mix-and-match” combinatorial biochemistry using 
enzymes from several hosts in one pathway, can circumvent issues with problematic 
enzymes and even expand the available range of products from an engineered 
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pathway.[35]  Additionally, advances in enzyme engineering have allowed the possibility 
of tailoring enzymes specifically for use in microbial heterologous biosynthetic 
pathways.[36]  Once the desired enzymes have been identified, the construction of 
heterologous expression plasmids can be achieved through a number of recently-
developed, high-throughput methods for DNA assembly techniques.[37]  Finally, after 
building a biosynthetic pathway, production optimization can be carried out through the 
alteration of enzyme expression and/or precursor pathway optimization.  One recently-
developed method for pathway optimization is multivariate modular metabolic 
engineering (MMME), in which discrete synthetic operon modules are simultaneously 
varied in copy number, promoter, ribosome binding site, etc. and screened for optimal 
pathway flux.[38]  Additionally, the importance of the spatial organization of biosynthetic 
enzymes is becoming apparent, and techniques are being developed to control the 
localization of heterologous enzymes in microbial hosts.[39]  When some or all of these 
techniques have been streamlined, significant progress has been made toward the 
microbial biosynthesis of a number of valuable plant natural products. 
4.2 Review of engineered plant phenylpropanoid pathways in microbes 
The vast majority of reports on the microbial biosynthesis of plant phenylpropanoids 
have involved the biosynthesis of flavonoid and stilbenoid compounds.  The first such 
study was published in 2003, in which E. coli overexpressing a plant PAL and CHS and 
a bacterial 4CL were fed L-tyrosine and L-phenylalanine and catalyzed their conversion 
to naringenin chalcone and pinocembrin chalcone, respecitvely.[40]  Soon after, Watts et 
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al. showed the production of narigenin chalcone from fed L-tyrosine in E. coli through the 
co-overexpression of a bacterial TAL and a plant 4CL and CHS.[11]  Since then, many 
studies have been published showing the production of naringenin (Scheme 1.1) using 
similar strategies in both E. coli and S. cerevisiae, mostly through the feeding of 
phenylpropanoid precursors (reviewed in [32]).  The same strategy has also been used for 
the production of stilbenoids such as resveratrol (Scheme 1.1), by replacing the CHS 
with a stilbene synthase (STS).[12, 41]  Through the course of these studies, it has become 
apparent that the limiting factor in microbial flavonoid biosynthesis, particularly in E. coli, 
is the limited malonyl-CoA pool within the cell.[32]  To circumvent this, some studies have 
increased the malonyl-CoA pool through overexpression of acetyl-CoA carboxylase and 
acetyl-CoA synthase and knockout of competing pathway enzymes, leading to a 
significant increase in flavonoid production.[42-43]  Still, the need to feed phenolic 
precursors such as aromatic amino acids or hydroxycinnamic acids is a limiting factor for 
flavonoid biosynthesis.  Recently, two studies have reported the de novo biosynthesis of 
flavanoids from glucose in E. coli and S. cerevisiae engineered for increased L-tyrosine 
metabolism, reaching up to ~300 mg/L naringenin in the yeast system.[44-45]  While these 
levels are not yet sufficient for industrial applications, the last decade has seen great 
strides in improvement of stilbenoid and flavonoid biosynthesis in microbes. 
 Relatively recently, there has been an increased interest in the microbial 
biosynthesis of hydroxycinnamic acids and their esters and amides, due to the evidence 
that this class of compounds makes up a large percentage of dietary anti-oxidant and 
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anti-inflammatory compounds.[21-23, 46]  The de novo biosynthesis of caffeic acid has been 
achieved in E. coli through overexpression of a bacterial TAL and a bacterial flavin 
monooxygenase Sam5 from Saccharothrix espanaensis capable of carrying out the 3-
hydroxylation of p-coumarate (Scheme 1.2).[47-48]  The additional co-expression of a 
caffeic acid o-methyltransferase from Arabidopsis thaliana in this system led to the 
biosynthesis of ferulic acid, an important precursor to monolignol biosynthesis.[47, 49]  It 
was also recently shown that E. coli’s native hydroxyphenylacetate-3-hydroxylase 
complex, HpaBC, is able to hydroxylate p-coumarate at the 3 position, and that its co-
overexpression with a TAL in E. coli leads to the de novo biosynthesis of caffeic acid 
(Scheme 1.2).[50]  Because most bioavailable plant hydroxycinnamic acids exist as esters 
and amides, and because of the potential pharmaceutical applications of some of these 
conjugates, the microbial biosynthesis of such compounds has also been pursued.[23, 46]  
The production of hydroxycinnamoyl shikimates and quinates, including chlorigenic acid 
(Scheme 1.1), the ester of caffeic acid and quinate, and hydroxycinnamoyl amide 
tyramine derivatives was first achieved in E. coli through feeding hydroxycinnamic acid 
precursors and overexpression of plant 4CL and hydroxycinnamoyl transferase 
enzymes.[51-53]  The more recent advances in de novo hydroxycinnamic acid biosynthesis 
in E. coli have allowed the possibility of synthesizing hydroxycinnamoyl esters and 
amides from glucose.  Eudes et al. recently showed the de novo biosynthesis of the 
hydroxycinnamoyl anthranilate avenanthramide D (Scheme 1.1) to 77 mg/L in an L-
tyrosine-overproducing strain of E. coli.[54]  On a similar scale, the de novo biosynthesis 
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of chlorigenic acid was recently achieved to 78 mg/L in E. coli through similar 
strategies.[55]  While still in its early stages, the development of microbial biosynthetic 
platforms for hydroxycinnamic acids and their esters and amides shows promise, and 
has benefited from previous research on microbial flavonoid and stilbenoid biosynthetic 
platforms.  
 Within just the last two years, the plant phenylpropanoid biosynthetic capabilities 
of E. coli have been further expanded to include additional compound classes.  For 
example, the biosynthesis of medically-important plant-specific coumarin compounds 
(Scheme 1.1) has been shown through the co-overexpression of caffeic acid 
biosynthetic enzymes with a plant caffeic acid ortho-hydroxylase.[56-57]  Additionally, co-
overexpression of genes from creosote bush encoding a cinnamoyl alcohol 
acyltransferase with either an allylphenol synthase or a propenylphenol synthase led to 
the production of eugenol (Scheme 1.1) or isoeugenol, important flavorants and 
antiseptics, from fed monolignol precursors.[58]  Finally, the bioconversion of the lignan 
(+)-pinoresinol to matairesinol, a precursor to the highly-valuable cancer pro-drug 
podophyllotoxin, has been achieved in E. coli through the overexpression of a fusion of 
the pinoresinol-lariciresinol reductase and secoisolariciresinol dehydrogenase (PLR-
SDH) enzymes from Podophyllum pleianthum, a plant that naturally produces 
podophyllotoxin.[59]  Clearly, the last decade of research on the biosynthesis of plant 
phenylpropanoids has laid the groundwork for a plethora of valuable compounds to 
eventually be synthesized from simple sugars in industrially-relevant organisms. 
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Scheme 1.2.  Aromatic amino acid biosynthesis (AAAB) in E. coli as a precursor to 
plant phenylpropanoid production.  AroG and TyrA are sensitive to feedback inhibition by 
L-tyrosine.  An example of a recombinant biosynthetic pathway for a plant-specific 
phenylpropanoid is boxed.  L-tyrosine overproduction has been achieved by overexpression 
of PpsA (PEP synthase) and TktA (transketolase), overexpression of feedback resistant 
mutants of AroG and TyrA, and knockout of the competing pathway enzyme PheA.  E4P, 
erythrose-4-phosphate; PEP, phosphoenolpyruvate; DAHP, 3-Deoxy-D-
arabinoheptulosonate 7-phosphate; DAHPS, DAHP synthase; CM, chorismate mutase; PDH, 
prephenate dehydrogenase; PDT, prephenate dehydratase; TAL, tyrosine ammonia lyase. 
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4.3 Metabolic engineering of the shikimate pathway for increased 
phenylpropanoid production  
In the last decade, alongside advancements in the microbial biosynthesis of 
phenylpropanoids through heterologous expression of plant pathways, researchers have 
discovered a number of ways to alter the native shikimate pathway of microbes for 
increased production of critical phenylpropanoid precursors, especially L-tyrosine 
(reviewed in [16]).  The most prevalent method has been to deregulate the AAAB 
pathway, which is tightly controlled via transcriptional regulation by TyrR and feedback 
inhibition of DAHP synthase (AroG in E. coli) and the PDT domain of CM-PDT (TyrA in 
E. coli) by L-tyrosine.  Knockout of the gene encoding TyrR and/or the overexpression of 
feedback-resistant mutants or chimeras of AroG and TyrA has consistently been shown 
to increase production of L-tyrosine and downstream phenylpropanoid products 
(Scheme 1.2).[17, 45, 48-49, 55, 60-61]  One group took a unique approach to AAAB 
deregulation by knocking out the post-transcriptional carbon storage regulator CsrA, 
which down-regulates PEP carboxykinase and PEP synthetase translation, leading to an 
increase in L-phenylalanine production.[62]  In addition to AAAB deregulation, many 
studies have increased phenylpropanoid production through the overexpression of PEP 
synthetase (PpsA) and transketolase (TktA), the enzymes giving rise to PEP and E4P 
and feeding the shikimate pathway (Scheme 1.2).[50, 54, 56, 60-61]  Because the 
PEP:carbohydrate phosphotransferase system (PTS) competes with the shikimate 
pathway for available PEP, some studies have used PTS- strains for the production of 
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aromatic compounds.[61, 63]  In an alternative approach to this problem, one group has 
evolved a 2-keto-3-deoxy-6-phosphogalactonate aldolase to convert pyruvate and E4P 
into DAHP, therefore eliminating the need to compete with PTS for available PEP.[64]  In 
some cases, when L-tyrosine is specifically needed as a phenylpropanoid precursor, the 
competing pathway towards L-phenylalanine has been blocked through knockout of the 
gene encoding CM-PDH (PheA) in E. coli, leading to an increase in L-tyrosine derived 
products (Scheme 1.2).[45, 48, 55]  In addition to the above rational approaches, random 
and combinatorial genetic approaches have been used to boost L-tyrosine biosynthesis 
through the development of a high-throughput screen for L-tyrosine.[65-67]  These 
techniques have collectively proven to be powerful tools for the development of 
economically-viable production of aromatic amino acids and their derivatives, with L-
tyrosine production levels reaching as high as 13.8 g/L.[67]  One notable example was the 
recent de novo biosynthesis of hydroxycinnamoyl anthranilates in E. coli by Eudes et al. 
(2013).[54]  AAAB deregulation through TyrR knockout and overexpression of feedback-
resistant AroG and TyrA, as well as overexpression of rate-limiting enzymes in the 
shikimate pathway led to an increase of more than 100-fold in avenanthramide D 
biosynthesis.[54]  These advances have illustrated the utility of E. coli as a host for 
heterologous plant phenylpropanoid biosynthetic pathways and have made significant 
strides toward the application of these platforms on an industrial scale.   
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5.  Metabolons in Microbial Natural Product Biosynthesis 
5.1 The importance of spatial organization in metabolic pathways 
In the past, scientists have simplified metabolism by looking at cells as “bags of 
enzymes,” and much of the study of biochemistry and enzymology has mimicked this 
notion through in vitro enzyme characterization.  However, the natural cellular 
environment paints a very different picture of metabolism in which highly-ordered spatial 
organization of enzymatic pathways leads to fine-tuned, efficient biocatalysis.  
Eukaryotes are well-known to organize metabolic pathways within organelles or tethered 
to lipid membranes.  Even the cells of prokaryotes such as E. coli, which we think of as 
having no organelles, has been shown to be 20 – 30% macromolecules by volume, [68] 
which significantly slows the rate of small molecule and metabolic enzyme diffusion.[69]  
In such an environment, colocalization of enzymatic pathways into so-called 
“metabolons” confers the advantages of metabolic channeling of pathway 
intermediates.[39]  Nature has taken a number of routes to evolving metabolons, including 
the creation of multi-functional enzymes, formation of multi-enzyme complexes, and 
localization to a sub-cellular organelle or compartment.[39]  Having enzyme active sites in 
close proximity reduces the required fusion distance of intermediates, making them more 
likely to undergo a reaction before diffusing away.  In the case of the Salmonella 
typhimurium L-tryptophan synthetase channel, this limitation of indole diffusion results in 
a one or two order of magnitude increase in catalytic efficiency.[70]  In addition to keeping 
local concentrations of intermediates high, metabolic channeling keeps cellular 
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concentrations low, which can prevent toxicity of harmful intermediates.  This is a distinct 
advantage conferred by bacterial microcompartments (BMCs) which encapsulate 
enzymes and toxic aldehyde intermediates involved in ethanolamine and 1,2-
propanediol utilization in a number of enteric bacteria.[71]  Furthermore, metabolons often 
provide a means of metabolic regulation and the prevention of cross-talk with other 
pathways.  For example, clusters of purine biosynthetic enzymes assemble into 
purinosomes in mammalian cells, but dissipate when the demand for purines 
decreases.[72]  It is believed that secondary metabolism is also dependent on the 
controlled spatial arrangement of enzymes, usually involving dynamic, low-affinity 
protein-protein interactions.  There is strong evidence for metabolic channeling in plant 
natural product biosynthesis, including phenylpropanoid biosynthesis, which involves the 
interaction of several enzymes with membrane-bound cytochrome P450s.[73]  Based on 
this knowledge, it is crucial to understand and, if possible, manipulate the spatial 
arrangement of enzymes when building heterologous biosynthetic pathways in microbes. 
5.2 Synthetic metabolons for microbial production platforms 
Since early in the history of microbial metabolic engineering, researchers have 
attempted to increase the flux through biosynthetic pathways by creating synthetic 
metabolons.  The most common way to do this has been through the creation of fusion 
proteins.  In most cases, the fusion of two or more biosynthetic enzymes has resulted in 
an increase in catalytic efficiency and/or metabolic flux through a pathway (reviewed in 
[39]).  In a recent example, the percent bioconversion of pinoresinol to matairesinol by E. 
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coli expressing PLR and SDH enzymes from P. pleianthum was three fold higher when 
the enzymes were expressed as a PLR-SDH fusion.[59]  Interestingly, the creation of 
fusion proteins has also been the result of a non-rational strain engineering endeavor.  
Meynial et al. evolved E. coli containing a plasmid with two open reading frames for 
glycerol biosynthesis, and the final selected high-titer production strain showed a 
deletion between the ORFs resulting in an in-frame fusion of the two proteins.[74]  While 
creating a fusion protein is a simple way to bring enzymes into close proximity, there are 
a number of limitations with this approach.  First, most biosynthetic enzymes are active 
as multimeric proteins, and creation of a protein fusion can interfere with oligomer 
formation.[39]  Second, the folding of large multi-domain heterologous proteins can be 
problematic in microbes and is especially inefficient in bacterial hosts.[75]  In fact, while 
Kuo et al. discovered that the PLR-SDH fusion increased lignan bioconversion, the 
fusion in the opposite conformation, with SDH at the N-terminus (SDH-PLR), only 
exhibited PLR activity.[59]  In light of these setbacks, there is a need for a means of 
enzyme colocalization that can allow enzymes to take their native conformations as 
much as possible. 
 In recent years, a new, post-translational approach to creating synthetic 
metabolons has emerged based on the model of bacterial cellulosomes.  Bacterial 
cellulosomes consist of a long scaffold containing several cohesin domains and several 
cellulase enzymes that bind to the scaffold via dockerin domains.  Engineered 
cellulosomes in E. coli, using distinct cohesin-dockerin domain pairs from different 
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species, leads to an increase in the degradation of recalcitrant cellulose over free 
cellulase enzymes (reviewed in [39]).  Additionally, it was shown that different geometric 
arrangements of enzymes on the scaffold affects cellulose degradation, suggesting that 
tight control of enzyme colocalization on synthetic scaffolds could be a valuable tool in 
biocatalysis.[76]  In 2009, this approach was expanded with the development of a 
completely synthetic scaffold system in E. coli, utilizing eukaryotic protein interaction 
domains to control the number and arrangement of enzymes in a metabolon.[77]  Using 
the three enzymes in the S. cerevisiae mevalonate pathway as a proof of concept, 
Dueber et al. showed that synthetic scaffolding significantly increased pathway flux, and 
that altering the architecture and enzyme stoichiometry of the metabolon influenced 
pathway productivity.[77]  Since then, studies have used this scaffolding system to 
optimize the biosynthesis of glucaric acid in E. coli[78] and the production of resveratrol in 
S. cerevisiae.[79]  Meanwhile, another group developed an alternative means of protein 
scaffolding, by equipping metabolic enzymes with zinc finger domains designed to bind 
to specific sequences of DNA.  Through overexpression of zinc finger-containing 
metabolic enzymes in the same cell as a scaffold sequence-containing plasmid, 
Conrado et al. showed an increase in violacein biosynthesis in E. coli.[80]  Additionally, 
Delebecque et al. have developed an RNA-based scaffolding system, using RNA 
molecules designed with specific aptamer sequences to bind metabolic enzymes, 
leading to an increase in efficiency of a hydrogen production pathway in E. coli.[81]  The 
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use of these scaffold-based engineered metabolons shows great promise for application 
in the microbial biosynthesis of plant natural products. 
 An alternative approach to engineering metabolons in bacterial systems is the 
encapsulation of metabolic enzymes in protein-based shells.  In nature, bacteria have 
evolved the encapsulins and bacterial microcompartments (BMCs) to achieve this.  
Encapsulins are small compartments made up of a single shell protein that encapsulate 
ten to twenty copies of a single oxidative stress-related enzyme, such as a peroxidase or 
ferritin-like protein.[82]  A C-terminal cargo-protein motif was identified that is necessary 
for encapsulation, although it has never been tested with heterologous enzymes.[82]  
However, other groups have engineered simple charged tags on the interior of the 
encapsulin shell protein and the C-terminus of the cargo protein and achieved 
encapsulation of both eGFP[83] and HIV protease.[84]  While engineered encapsulins are 
useful for sequestering single enzymes, particularly enzymes like HIV protease which 
are toxic to E. coli, their applications are limited in metabolic engineering due to the 
small number of enzymes encapsulated within each.   
 BMCs, on the other hand, are much larger and have evolved in nature to 
sequester a large number and variety of enzymes.  The most well-known forms of BMCs 
are the carboxysomes, which sequester the dark reactions in cyanobacteria, and the 
1,2-propanediol utilization (Pdu) and ethanolamine utilization (Eut) microcompartments, 
which encapsulate the enzymes required for catabolism of these compounds in enteric 
bacteria.[71]  BMC shells are made up of multiple proteins containing a conserved BMC 
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domain (PF00936) which self-assemble into sheets of hexamers that make up an 
icosahedral shell.  Recombinant expression of suites of shell proteins from the S. 
enterica Pdu BMCs,[85] the Halothiobacillus neapolitaus CsoS carboxysomes,[86] and the 
S. enterica Eut BMCs [87] has led to the formation of empty BMC shells in E. coli.  
Additionally, short, N-terminal signal peptides have been shown to be required for 
localization of enzymes into Pdu BMCs,[88-89] and Choudhary et al. have identified a 
signal peptide both necessary and sufficient for encapsulating recombinant proteins to 
Eut BMC shells in E. coli.[87]  Interestingly, it was found that in the Eut BMC system, 
overexpression of only one BMC domain shell protein, EutS, is required for recombinant 
shell formation,[87] making Eut BMCs an attractive platform for future engineered 
metabolons.  An interesting potential advantage of BMCs over scaffold-based systems is 
the fact that different BMC-domain protein hexamers form isotopically distinct pores in 
the center, opening up the possibility to engineer the selective permeability of BMC 
shells.[90-91]  While BMCs have yet to be utilized successfully in the construction of an 
engineered metabolon containing multiple enzymes, the use of this system shows great 
promise for the in vivo colocalization of heterologous biosynthetic pathways. 
6. Thesis Motivation and Preliminary Work 
I was drawn to Dr. Schmidt-Dannert’s laboratory by two main interests: plant natural 
products biosynthesis and microbial engineering.  I chose to pursue work related to the 
bacterial production of bioactive plant phenylpropanoids, drawing from previous work in 
the lab to establish the biosynthesis of flavonoid and stilbene production in E. coli.[11-12]  I 
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attempted to expand the repertoire of plant phenylpropanoids that can be produced in 
plants by incorporating heterologous biosynthetic pathways for two classes of products 
that had not yet been produced in E. coli.  Additionally, I worked to develop recombinant 
BMCs as a means of directing the spatial organization of enzymes involved in 
heterologous biosynthetic pathways. 
6.1 Lignan biosynthesis in E. coli 
In 2009, I began work on a project in collaboration with Dr. Jacob Vick to engineer the 
first microbial strain capable of producing lignans from an inexpensive feedstock.  
Lignans are valuable for their anti-oxidant and phytoestrogen properties.  We were 
particularly interested in the biosynthesis of podophyllotoxin, an extremely cytotoxic 
compound and an important precursor to widely-used chemotherapy drugs.[92]  At the 
time this work was begun, none of the intermediates in plant lignan biosynthesis beyond 
p-coumaric acid had been produced in E. coli.  The ultimate goal of this work was to 
establish the bioconversion of a cheap feedstock, ferulic acid, to matairesinol, the latest 
precursor to podophyllotoxin whose biosynthesis has been fully elucidated.[93]  The work 
was broken down into three parts.  First, Dr. Vick worked to establish the bioconversion 
of ferlulic acid into the monolignol coniferyl alcohol through the overexpression of three 
enzymes from A. thaliana.  Second, I worked to establish the regio- and stereo-selective 
coupling of coniferyl alcohol to (+)-pinoresinol in E. coli through the expression of a 
bacterial laccase and a dirigent protein.  Finally, I planned to establish the conversion of 
(+)-pinoresinol by matairesinol through overexpression of genes encoding PLR and SDH 
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from A. thaliana.  Because of the difficultly of dirigent protein expression in E. coli and 
the publication of the bioconversion of (+)-pinoresinol to matairesinol in E. coli before the 
completion of this work,[59] I have only reported the study of dirigent-mediated oxidative 
radical coupling in this thesis (Chapter 2). 
6.2 Hydroxycinnamic acid ester biosynthesis in E. coli 
Because of the consistent difficult of establishing regio- and stereo-specific coupling for 
lignan biosynthesis in E. coli, I decided to pursue a second project focusing on a 
different class of plant phenylpropanoids: the hydroxycinnamic acid esters (HCEs).  
These are important dietary anti-oxidant and anti-inflammatory compounds, and one 
HCE in particular, rosmarinic acid (RA), has been shown in in vitro and animal studies to 
have potent anti-cancer and neuroprotective activities.[23, 94]  While the bioconversion of 
hydroxycinnamoyl amides from fed hydroxycinnamic acid precursors had previously 
been established in E. coli,[52-53] the production of HCEs had not yet been published.  In 
plants, the meta-hydroxylation of the phenylpropanoid moieties in RA biosynthesis is 
carried out by microsomal cytochrome P450s after ester formation,[23] posing a 
significant obstacle to the de novo biosynthesis of RA in plants.  However, the beginning 
of this work in late 2011 coincided with the first report of caffeic acid biosynthesis in E. 
coli,[47] which allowed me to redesign the biosynthetic pathway to carry out meta-
hydroxylation prior to ester formation using a bacterial enzyme.  I used this approach to 
design and assemble a de novo biosynthetic pathway for RA specifically tailored to E. 
coli, utilizing bacterial enzymes wherever possible and shortening the biosynthetic route. 
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6.3 Study of enzyme encapsulation within recombinant Eut BMCs 
After the laboratory’s publication of recombinant protein encapsulation within 
recombinant Eut BMC shells,[87] Dr. Schmidt-Dannert’s group has focused on 
understanding recombinant Eut BMC biogenesis and developing tools for the creation of 
synthetic metabolons within this system.  I discovered cross-talk leading to undesired 
products in my engineered RA biosynthetic pathway and devised a model for how partial 
encapsulation of the pathway within a BMC shell could prevent such cross-talk.  
Therefore, I carried out preliminary experiments to attempt localization of RA 
biosynthetic enzymes to engineered Eut BMCs using the EutC1-19 signal peptide 
discovered by Choudhary et al.[87]  This led me to conceptualize and begin work on a 
study of the mechanism of enzyme encapsulation within recombinant Eut BMCs, with 
the ultimate goal of understanding how to fine-tune control of multiple enzyme 
encapsulation.  This work is being completed in collaboration between myself, Dr. Mark 
Held and Suzie Hsu, and will be continued by Dr. Sarah Perdue and Kelsey Dahlgren 
upon my graduation. 
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Chapter 2. Towards Microbial Lignan Biosynthesis: Exploring 
Oxidative Radical Coupling in Escherichia coli. 
Summary 
Lignans are bioactive plant phenylpropanoids derived from monolignols.  The most 
commercially important lignan, podophyllotoxin (PTOX), is in high demand as a 
chemotherapy pro-drug.  Due to the depletion of source plant populations and the 
infeasibility of chemical synthesis, a microbial production platform would be extremely 
valuable. Lignan biosynthesis begins with the regio- and stereo-selective coupling of two 
coniferyl alcohol radicals to form (+)-pinoresinol, which is driven by molecular 
chaperones called dirigent proteins.  In this work, I aimed to establish (+)-pinoresinol 
production in E. coli by coexpressing a dirigent protein and a laccase that can generate 
coniferyl alcohol radicals.  I showed that SLAC, a small laccase from Streptomyces 
coelicolor, is able to oxidize coniferyl alcohol and give racemic pinoresinol in E. coli.  I 
was also able to establish the soluble expression of a well-characterized dirigent protein 
from Forsythia intermedia, FiDRP1, through co-overexpression with E. coli protein-
folding chaperones.  Ultimately, I was unable to show function of the E. coli-expressed 
FiDRP1.  Meanwhile, another group has shown that post-translational modifications are 
essential for dirigent protein function.  This suggests that E. coli is not a viable host for 
lignan biosynthesis, and that a eukaryotic host may be more feasible. 
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1. Introduction 
Lignans are class of polyphenolic plant natural products known for their potent biological 
activities.  Derived from monolignols, the same monomeric units that make up lignin, 
lignans are widespread among vascular plants and make up a significant portion of 
important dietary antioxidants.[95]  Lignans are also phytoestrogens – food-derived 
compounds whose metabolites mimic estrogens in the human body – which have been 
shown to be important as preventatives of cardiovascular disease based on their 
antioxidant and anti-inflammatory properties, as well as their positive effects on vascular 
smooth muscle, endothelial cells, and extracellular matrix.[96-97]  Some lignans and their 
derivatives are also important pharmaceuticals.  Podophyllotoxin (PTOX), a lignan found 
in the roots of plants the genus Podophyllum (may apples), and its close analog 
deoxypodophyllotoxin (DPT) are microtubule inhibitors that exhibit strong anti-mitotic 
activity, making them potent anti-tumor and anti-viral treatments (Scheme 2.1).[93, 98]  
While PTOX is too cytotoxic to be used for chemotherapy, three of its derivatives – 
etoposide, teniposide and etopophos – are widely used in the chemotherapeutic 
treatment of several cancers such as leukemia, lymphoma, testicular cancer, and small-
cell lung cancer.[93] 
The primary means of producing PTOX remains the same as it has for centuries: 
extraction from plants which naturally produce the compound.  Unfortunately, plants of 
the species Podophyllum are not easily cultivated, and wild sources of the plants – 
especially the population of P. hexandrum in the Himalayas – are being depleted.[99]  
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Meanwhile, the steadily increasing demand for PTOX necessitates the development of a 
sustainable means of mass production.  Four chiral centers in the PTOX molecule make 
synthesis economically impossible due to low yields.[92]  Some groups have reported the 
production of PTOX in plant cell and tissue cultures; however, the yields are insufficient 
for this method to be implemented on an industrial scale.[99]  Given all of these setbacks, 
a microbial production platform for PTOX and related lignans could be an attractive 
 
Scheme 2.1.  Biosynthesis of valuable lignans PTOX and DPT in plants.  The 
monolignol coniferyl alcohol is derived from L-phenylalanine through a well-characterized 
biosynthetic pathway.  A single electron oxidase, likely a laccase, and a molecular chaperone 
called a dirigent protein catalyze the regio- and stereo-specific coupling of two coniferyl 
alcohol radicals to (+)-pinoresinol.  Two enzymes, pinoresinol-lariciresinol reductase (PLR) 
and secoisolariciresinol dehydrogenase (SDH) catalyze the conversion of (+)-pinoresinol to (-
)-matairesinol.  Finally, several undiscovered enzymatic conversions lead to the biosynthesis 
of the valuable lignans podophyllotoxin (PTOX) and deoxypodophyllotoxin (DPT). 
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option, allowing for the inexpensive, renewable production of these value-added lignans 
with the desired stereochemistry and precise regulatory control.  While the biosynthetic 
pathway of PTOX has not yet been fully elucidated in plants,[92]  enough is understood to 
begin the lay the groundwork for a heterologous biosynthetic pathway in microbes. 
The biosynthesis of PTOX in plants begins with the biosynthesis of the 
monolignol coniferyl alcohol via the shikimate and aromatic amino acid pathways 
(Scheme 2.1).  In lignin biosynthesis, coniferyl alcohol and other monolignols undergo 
single-electron oxidation by a laccase or peroxidase and are randomly incorporated into 
growing lignin polymers through oxidative radical coupling.  The first step in lignan 
biosynthesis, however, requires the controlled regio- and stereo-selective coupling of 
two monolignol radicals – in the case of PTOX, two coniferyl alcohol radicals are linked 
at the 8 – 8’ positions to form (+)-pinoresinol.  The mechanism of this selective oxidative 
radical coupling was first elucidated by Davin et al., who showed that this process 
depends on a molecular chaperone called a dirigent protein to guide the proper 
alignment of two monolignol radicals and give a specific product (Scheme 2.2).[100]  
Dirigent proteins have no catalytic center and are unable to oxidize monolignols; rather, 
they are thought to bind free monolignol radicals in a specific conformation to facilitate 
controlled coupling.[101-102]  After oxidative radical coupling, the enzymes pinoresinol-
lariciresinol reductase (PLR) and secoisolariciresinol dehydrogenase (SDH) convert (+)-
pinoresinol stereoselectively to (-)-matairesinol, which is subsequently converted to 
PTOX in four or five unknown enzymatic steps (Scheme 2.1). 
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The most critical step in the creation of a microbial biosynthetic platform for 
valuable (+)-pinoresinol-derived lignans such as PTOX is to establish controlled 
oxidative radical coupling in a widely-used microbial host.  To this end, we have explored 
the possibility of engineering the regio- and stereo-selective coupling of coniferyl alcohol 
 
Scheme 2.2. Mechanism of stereo- and regio-specific oxidative radical coupling.  After 
oxidation by a laccase or peroxidase, in the absence of a dirigent protein, coniferyl alcohol 
undergoes random coupling to give racemic mixtures of 8-5’, 8-8’ and 8-O-4’ linked dimers.  
The dirigent protein binds free coniferyl alcohol radicals, orients them for stereospecific 8-8’ 
linkage, and leads to the production of an enantiomeric excess of (+)-pinoresinol.  SLAC, 
small laccase from Streptomyces coelicolor; FiDRP1, characterized (+)-pinoresinol-forming 
dirigent protein from Forsythia intermedia. 
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to (+)-pinoresinol in Escherichia coli.  We first established the expression and in vivo 
function of a bacterial single electron oxidase capable of generating coniferyl alcohol 
radicals.  Then, we explored the expression and function of two dirigent proteins in E. 
coli, one dirigent from Forsythia intermedia well-characterized for (+)-pinoresinol 
formation and another putative dirigent protein from A. thaliana.  We found the 
expression of dirigent proteins in E. coli to be extremely problematic, and were unable to 
establish the function of the heterologously-expressed (+)-pinoresinol-forming dirigent 
protein.  Ultimately, this and recent work published by other groups have illustrated the 
impossibility of establishing dirigent protein function in E. coli.  For future engineering of 
lignan biosynthetic pathways in microbes, we recommend the use of a well-understood 
eukaryotic host instead. 
2. Results 
2.1 Oxidative coupling of coniferyl alcohol to racemic pinoresinol in E. coli by 
SLAC, a small laccase from Streptomyces coelicolor 
The first component required to achieve stereoselective oxidative radical coupling is an 
enzyme capable of single-electron oxidation of monolignol precursors.  In plants, this is 
believed to be carried out by one or more nonspecific laccase or peroxidase enzymes.[27, 
100]  Laccases are multi-copper single electron oxidases that can oxidize a broad range 
of phenolic compounds, and have received much attention in recent years for their 
current and potential applications in the textile industry,[103] bioremediation[104-105] and 
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biocatalysis,[106] with fungal laccases being the most abundant and well-
characterized.[107]  However, because the expression of fungal enzymes can be 
problematic in a bacterial host, we desired a bacterial laccase for use in biosynthetic 
applications in E. coli.  A small laccase from Streptomyces coelicolor, called SLAC, had 
previously been expressed in E. coli and shown to have remarkable stability and high 
activity at neutral pH, unlike many fungal laccases.[108]  We hypothesized that SLAC 
would be able to oxidize coniferyl alcohol and lead to the production of racemic 
pinoresinol, among other di- and polyphenol compounds.  We therefore amplified the 
gene encoding SLAC from S. coelicolor genomic DNA and cloned it into the plasmid 
pUCmodRBS, a high-copy plasmid with a modified constitutive lac promoter, in frame 
with a C-terminal His-tag.  Transformation of E. coli BW27784 cells with pUCmodRBS-
SLAC led to the overexpression of the SLAC enzyme, which was easily enriched via Ni2+ 
affinity purification (Figure 2.1).  Two predominant bands are visible in the SLAC 
purification: a band at ~37 kDA, corresponding to the predicted size of the SLAC 
monomer, and a band at ~75 kDA, which is roughly the size of dimerized SLAC.  Indeed, 
the previous characterization of this enzyme showed the presence of active, dimeric 
SLAC under the denaturing conditions of SDS-PAGE, speaking to the extreme stability 
of this enzyme.[108]  Incorporation of copper ions was facilitated by dialysis of the purified 
enzyme in a copper-containing buffer. 
 Having purified SLAC, we initially tested it for activity with coniferyl alcohol 
through an in vitro assay.  SLAC was incubated with 4 mM coniferyl alcohol at 30 °C,  
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and samples were taken over time, extracted with ethyl acetate and analyzed via HPLC.  
We observed the depletion of coniferyl alcohol from the reaction over time, as well as the 
appearance of a peak corresponding to pinoresinol within 20 min, suggesting that SLAC 
is indeed able to oxidize coniferyl alcohol (Figure 2.2).  Several other peaks, which likely 
correspond to other di- and poly-lignol coupling products, were observed. Coniferyl 
alcohol completely disappeared within 120 min reaction time; however, the abundance 
of pinoresinol and the other products remains stable between 40 and 60 min, and even 
seems to have decreased at 120 min.  This is likely due to the non-specific nature of 
laccases – SLAC may have been further oxidizing the dimeric lignan products further to 
higher-order polyphenols, which were then lost in the extraction process.  In fact, we 
observed a white solid that remains at the interface of the aqueous and organic phases 
 
Figure 2.1.  Expression and purification of SLAC from E. coli BW27784 cells.  Cells 
were transformed with pUCmodRBS-SLAC, cultured to mid-log phase at 37 °C, and moved 
to a 20 °C shaker and incubated for 20 h before harvesting and lysis.  Purification was carried 
out via FPLC on a 5-mL Ni
2+
 column.  Lys, lysate; ft, flowthrough. 
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during ethyl acetate extraction which appears to increase in abundance over time, which 
was likely due to the formation of large, polyphenol molecules. 
 
 
Figure 2.2. In vitro oxidation of coniferyl alcohol to pinoresinol and other products by 
SLAC. Purified SLAC (20 μg/mL) was incubated with 4 mM coniferyl alcohol in 100 mM Tris 
pH 8.0 at 30 °C with shaking.  Every 20 min, samples were taken and immediately extracted 
with ethyl acetate for subsequent HPLC analysis.  Vertical dashed lines indicate the retention 
times of coniferyl alcohol and pinoresinol peaks, as compared to analytical standards. 
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 Next, to gauge SLAC’s potential utility in microbial lignan biosynthesis, we tested 
whether heterologous expression of SLAC allowed E. coli to convert exogenous coniferyl 
alcohol to pinoresinol.  E. coli BW27784 were transformed with pUCmodRBS-SLAC or 
empty pUCmodRBS as a negative control and cultured in modified minimal media 
supplement 100 μM coniferyl alcohol.  Because initial screens using crude E. coli cell 
lysates containing SLAC gave little detectable coniferyl alcohol oxidation (data not 
shown), these cultures were also supplemented with copper sulfate to ensure 
 
Figure 2.3. Oxidation of coniferyl alcohol to pinoresinol by E. coli BW27784 cells 
expressing SLAC.  E. coli BW27784 cells were transformed with pUCmodRBS (empty) or 
pUCmodRBS-SLAC. Transformants were cultured in modified minimal media at 30 °C; 3 h 
after inoculation, cultures were supplemented with 100 μM coniferyl alcohol and 100 μM 
copper sulfate.  Culture samples were taken over time, cleared of cells, and extracted with 
ethyl acetate for HPLC analysis. An analytical standard of pinoresinol was used to confirm 
peak identity and quantification.  Asterisks denote statistical significance at p ˂ 0.05 
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incorporation of copper into the active site of SLAC.  Ethyl acetate extraction and HPLC 
analysis of the culture media showed the accumulation of up to 11 ± 1 μM pinoresinol in 
cells expressing SLAC (Figure 2.3).  Surprisingly, a peak at the retention time of 
pinoresinol (53 min) was also detected in cells transformed with empty vector.  However, 
at 8 h and 24 h, cultures transformed with pUCmodRBS-SLAC exhibit a significantly 
higher apparent concentration of pinoresinol than cultures transformed with empty vector 
(p ˂ 0.05), which suggests that SLAC expression leads to the oxidation of coniferyl 
alcohol and the formation of pinoresinol in E. coli (Figure 2.3). 
2.2 Cloning and expression optimization of a characterized (+)-pinoresinol-forming 
dirigent protein from Forsythia intermedia 
The second essential component for lignan bisoynthesis in E. coli is the heterologous 
expression of a functional (+)-pinoresinol-forming dirigent protein.  Genes encoding 
dirigent and dirigent-like proteins are widespread among plants,[102, 109-110] but very few 
have been characterized biochemically.[111-113]  For the specific coupling of coniferyl 
alcohol to (+)-pinoresinol in our system, we chose the first and most well-characterized 
(+)-pinoresinol-forming dirigent protein from Forsythia intermedia, FiDRP1.[100]  An E. coli 
codon-optimized gene encoding FiDRP1 was assembled via overlap extension PCR of 
several synthetic DNA oligomers, excluding an N-terminal cell-wall targeting sequence 
present in the native protein.  This gene was cloned into pUCmodRBS with a C-terminal 
His-tag and transformed into E. coli BL21 (DE3) cells.  In an initial screen, expression of  
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FiDRP1 was not visible via SDS-PAGE; however, anti-His-tag western blotting revealed 
the presence of a band the approximate predicted size of FiDRP1 (~19 kDa) (Figure 
2.4).  The majority of the observed protein was present in the insoluble fraction, with 
some protein in the soluble fraction, and only a very faint band in the eluent from a 
small-scale batch purification with metal affinity resin.  Interestingly, there appears to be 
many smaller bands in the insoluble fraction, suggesting that the insoluble FiDRP1 is 
being degraded (Figure 2.4).  This apparent degradation and low binding to a metal 
affinity resin suggested misfolding of FiDRP1.  At the time of this study, there were no 
crystal structures or structural models of dirigent proteins; however, we noted a weak 
homology between dirigent proteins and allene oxide cyclases,[114] whose C-terminus is 
 
Figure 2.4. Degradation of FiDRP1 with a C-terminal His-tag in E. coli BL21 (DE3).  
Cells were transformed with pUCmodRBS (empty) or pUCmodRBS-FiDRP1-ctH6; 
transformants were cultured overnight at 30 °C, lysed by sonication, and subjected to anti-
His-tag western blotting.  The lane marked “L” is a molecular weight ladder; the lane marked 
“+” contains a 25-kDa His-tagged protein as a positive control. P, pellet; S, soluble fraction; 
E, eluent from a small-scale batch purification with Talon™ metal affinity resin. 
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involved in a salt-bridge between protein monomers.[115]  Therefore, we thought the C-
terminal His-tag of FiDRP1 may be interfering with folding and/or quaternary structure 
formation and began exploring other expression options.  
 We first re-cloned FiDRP1 into pUCmodRBS with no His-tag and transformed the 
construct into E. coli BL21 (DE3) cells.  While cultures of these transformants exhibited 
some noticeable expression of FiDRP1, protein was only visible in the insoluble fraction 
after lysis (Figure 2.5).  To achieve higher expression levels, and for ease of future 
protein purification, FiDRP1 was also cloned into pET15b, which contains an in-frame N-
terminal His-tag and thrombin cleavage site.  Transformation of E. coli with pET15b-
FiDRP1 resulted in the very high expression of FiDRP1, but again, all protein was found 
 
Figure 2.5. Insoluble expression of FiDRP1 with no His-tag in E. coli BL21 (DE3).  Cells 
were transformed with pUCmodRBS (empty) or pUCmodRBS-FiDRP1, transformants were 
cultured at 30 °C, sampled periodically, lysed by sonication, and subjected to SDS-PAGE.  
The black arrow indicates the band corresponding to FiDRP1 (predicted size: ~18 kDa). 
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in the insoluble fraction, even at low temperatures (Figure 2.6).  In an attempt to 
increase the solubility of FiDRP1, we cotransformed pET15b-FiDRP1 with three 
plasmids for the arabinose-inducible overexpression of native E. coli protein folding 
chaperones to increase the protein-folding capacity of the host cells.  One plasmid, 
encoded the expression of GroEL and GroES, another DnaK, DnaJ and GrpE, and a 
third Tf (trigger factor).  When small-scale cultures of the transformants reached mid-log 
phase, FiDRP1 and chaperone expression were induced by the addition of IPTG and 
arabinose, respectively.  After 2.5 h induction at 30 °C, only cotransformation with 
pKJE7, encoding DnaK, DnaJ and GrpE, led to some soluble expression of FiDRP1 that 
was visible via SDS-PAGE (Figure 2.7).  Scale up to a 1-L culture and induction at 37 °C 
 
Figure 2.6. Insoluble expression of FiDRP1 with an N-terminal His-tag in E. coli BL21 
(DE3).  Cells were transformed with pET15b (empty) or pET15b-FiDRP1, and transformants 
were cultured to mid-log phase at 37 °C; then, half of the cultures were induced with IPTG 
(1mM), and all were moved to 30 °C or 16 °C shakers for 4 h induction.  Cells were lysed by 
sonication, and subjected to SDS-PAGE.  The black arrow indicates the band corresponding 
to FiDRP1 with the His-tag and thrombin cleavage site present in the pET15b vector 
(predicted size: ~21 kDa). 
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for 2.5 h led to high levels of soluble FiDRP1 expression (Figure 2.8); however, when 
this cell lysate was used to attempt the purification of FiDRP1, the His-tagged protein 
repeatedly failed to bind to a metal affinity resin. 
 
 
Figure 2.7.  Cotransformation E. coli BL21 (DE3) with pKJE7 and pET15b-FiDRP1 
leads to the soluble expression of FiDRP1. Cells were transformed with pET15b (empty), 
pKJE7 alone, pET15b-FiDRP1 or pET15b-FiDRP1 and pET15b.  Transformants were 
cultured to mid-log phase at 37 °C, at which point they were induced with either IPTG (1 
mM), arabinose (0.2 %w/v), neither, or both, and all were moved to a 30 °C shaker for 2.5 h 
induction.  Cells were lysed by sonication, and subjected to SDS-PAGE.  Red arrows 
indicate the expression of the overexpressed protein-folding chaperones; black arrows 
indicate bands corresponding to FiDRP1 with the His-tag and thrombin cleavage site 
present in the pET15b vector (predicted size: ~21 kDa). 
 42 
 
 
Although we were unable to purify the His-tagged FiDRP1 protein, we decided to 
conduct a preliminary test of dirigent function using a crude cell lysate containing soluble 
FiDRP1.  Previous studies of dirigent proteins had shown that, when assaying dirigent 
function, it is important to achieve a slow rate of monolignol oxidation, such that the 
random coupling of two radicals does not outpace the binding of the radicals to the 
dirigent protein.[100-101]  Therefore, we adapted an assay for dirigent function used 
previously by other groups, using flavin mononucleotide (FMN) as a non-specific oxidant 
of coniferyl alcohol.  E. coli BL21 (DE3) cell lysate containing soluble FiDRP1 (Figure 
2.8) was incubated with coniferyl alcohol and FMN for 4 h at 30 °C, after which the 
 
Figure 2.8.  High levels of soluble FiDRP1 expression in E. coli BL21 (DE3).  
Transformants of pET15b-FiDRP1 and pKJE7 were cultured to mid-log phase in 1 L LB 
media at 37 °C, at which point they were induced with both IPTG (1 mM) and arabinose (0.2 
%w/v) and incubated at 37 °C for a further 2.5 h.  Cells were lysed by sonication, and 
samples were subjected to SDS-PAGE.  Red arrows indicate the expression of the 
overexpressed protein-folding chaperones; black arrow indicates the band corresponding to 
FiDRP1 with the His-tag and thrombin cleavage site present in the pET15b vector (predicted 
size: ~21 kDa). 
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reaction was immediately extracted with ethyl acetate and prepared for HPLC.  First, 
samples were run on a C18 column for the separation of pinoresinol from other media 
components (Figure 2.9A); the pinoresinol collection from this run was then collected, 
concentrated, and subjected to chiral separation for the detection of (+)- and (-)-
pinoresinol enantiomers (Figure 2.9B).  In the presence of the cell lysate containing 
 
Figure 2.9. Preliminary test of FiDRP1 dirigent function using crude cell lysates.  A 
crude cell lysate containing high levels of soluble FiDRP1 (Figure 8) was incubated with 4 
mM coniferyl alcohol and 1 mM FMN for 4 h in HEPES-MES-acetate buffer (pH 5.0) with 75 
mM Na2SO4 at 30 °C.  Then the reaction was immediately extracted with ethyl acetate and 
prepared for reverse phase and chiral HPLC.  A) Reverse-phase separation of pinoresinol 
from other media components.  Vertical lines indicate the fraction collected for subsequent 
concentration and chiral separation.  B) Chiral separation of pinoresinol enantiomers. 
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FiDRP1, we were unable to detect any relative increase in formation of the (+)-
pinoresinol enantiomer, or any decrease in the formation of the (-)-pinoresinol 
enantiomer, suggesting that FiDRP1 is non-functional in E. coli.  Oddly, we detected the 
formation of some racemic pinoresinol in the samples even when FMN was not present 
(Figure 2.9); we suspect this may be due to some other nonspecific oxidant present in 
the cell lysate, which made up a large portion of the total reaction volume in the assay. 
2.3 Cloning and attempted expression of putative dirigent protein from 
Arabidopsis thaliana in E. coli 
While putative dirigent-protein-encoding genes are widespread in vascular 
plants, at the time this work was begun, only one dirigent protein, FiDRP1, had been 
cloned and characterized.  We therefore attempted to clone and express three putative 
dirigent proteins from Arabidopsis thaliana – AtDRP2, AtDRP3, and AtDRP5 – for future 
biochemical characterization.  Both truncated (omitting the N-terminal signal peptide) 
open reading frames of the three genes were amplified from A. thaliana cDNA and 
cloned into pUCmodRBS with C-terminal His-tags.  Colonies of some of the resulting 
plasmids showed an unusual, translucent phenotype on agar plates, suggesting to us 
that the genes may be toxic to E. coli when expressed constitutively.  Therefore, the 
open reading frames (including His-tags) were re-cloned into pBADmod1, which 
contains an arabinose-inducible promoter.  When E. coli BW27784 was transformed with 
these constructs, cultured to mid log-phase, and then supplemented with arabinose for 
expression induction, only one putative dirigent protein, AtDRP5, showed expression via 
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anti-His-tag western blotting (Figure 2.10).  Interestingly, as overall protein levels in the 
cell appeared to increase over time, a higher percentage of that protein appeared to 
aggregate and remain in the insoluble fraction during sample processing.  In fact, while 
overall expression levels were lowest 2 h after induction, all protein was soluble; 
however, at 24 h, very little soluble protein can be seen (Figure 2.10).  This clearly 
illustrated in AtDRP5 the same tendency to form insoluble aggregates that we and 
others had observed with FiDRP1,[116] and would later be observed by other groups 
characterizing AtDRPs.[117] 
 
 
Figure 2.10. Expression and aggregation of AtDRP5 in E. coli BW27784.  Cells were 
transformed with pBADmod1 (empty) or pBADmod1-AtDRP5-ctH6, cultured overnight at 37 
°C, and then moved to an 18 °C shaker after induction with arabinose (0.2 % w/v).  Cells 
were periodically harvested, lysed via sonication, and subjected to anti-His-tag western 
blotting. 
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3. Discussion 
3.1 SLAC as a single electron oxidase for lignan biosynthesis in E. coli 
We chose SLAC as a single electron oxidase for ease of expression in a bacterial host, 
in addition to its reported high activity.  We do in fact observe high levels of SLAC 
expression in E. coli with the same high stability reported in the literature (Figure 2.1).[108]  
We were also able to show that purified SLAC can oxidize coniferyl alcohol in vitro 
(Figure 2.2).  With supplementation of copper to the media, E. coli cells expressing 
SLAC were also able to oxidize coniferyl alcohol to pinoresinol at higher levels than cells 
transformed with empty plasmid (Figure 2.3).  In both in vitro and in vivo assays, the 
coniferyl alcohol was not stoichiometrically converted into pinoresinol. This is to be 
expected, as single-electron oxidation of coniferyl alcohol in the absence of a dirigent 
protein has been shown to result in a mixture of racemic pinoresinol, dehydro-diconiferyl 
alcohol, and erythro/threo-guaiacylglycerol coniferyl alcohol ethers.[27, 102]  However, 
levels of pinoresinol remained quite low and eventually decreased over time in both 
assays, even as coniferyl alcohol continued to be oxidized (Figures 2.2 and 2.3).  Based 
on the widespread reported promiscuity of laccases,[106-107] this is likely due to the further 
oxidation and crosslinking of pinoresinol and other dimeric products, forming larger 
polymers which are not visible via our analytical methods.  SLAC’s promiscuous activity 
could be problematic for use in heterologous phenylpropanoid biosynthetic pathways, as 
any downstream product retaining a phenolic ring may be subject to further oxidation 
and crosslinking.  Ideally, an oxidase with a high specificity for coniferyl would 
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circumvent this problem; unfortunately, to our knowledge, no such enzyme has been 
reported in the literature.  However, we note that in the in vitro assay, a decrease in 
pinoresinol levels does not occur until late in the assay, when all of the coniferyl alcohol 
has been depleted (Figure 2.2).  This suggests that the presence of high concentrations 
of a competing substrate may competitively slow the oxidation of lignan products.  
Likewise, decreasing the level of SLAC enzyme present by slowing 
transcription/translation rates could prevent the oxidation of downstream products.  
However, both of these approaches would also cause a decrease in coniferyl alcohol 
oxidation.  Because of the lack of specific single-electron oxidases for monolignols, a 
laccase such as SLAC is the best option for heterologous biosynthesis of lignans; 
however, this approach has an inherent flaw in the promiscuous nature of laccases. 
3.2 Dirigent proteins are inherently problematic in bacterial hosts. 
We encountered extreme difficulty in attempting the soluble expression of dirigent 
proteins in E. coli.  FiDRP1 was only solubly expressed at useful levels when E. coli 
protein folding chaperones were also overexpressed (Figure 2.7 and 2.8), suggesting 
that protein folding is a significant hindrance to the expression of dirigent proteins in 
bacteria.  Both FiDRP1 (Figures 2.4-2.6) and AtDRP5 (Figure 2.10) exhibited a tendency 
to aggregate in E. coli, suggesting that this may be a common problem among dirigent 
proteins, rather than a problem specific to one of them.  We are currently unable to 
explain the inability of soluble N-terminally His-tagged FiDRP1 to bind to a metal affinity 
resin; this could be due to burial of the His-tag in the quaternary structure of the protein, 
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or potentially aggregation of FiDRP1 during the purification process.  In the absence of 
purified protein, an assay using a crude cell lysate with high levels of FiDRP1 gave no 
evidence of dirigent function (Figure 2.9). 
During the completion of this work, two studies were published which validated 
our difficulties with functional dirigent protein expression in E. coli.  First, Pickel et al. 
published a structural study and a molecular model of a dirigent protein from A. thaliana, 
AtDIR6, using a crystal structure of an allene oxide cyclase as a template.  This model 
established AtDIR6 and FiDRP1 as homodimeric, all-barrel proteins, showed the 
presence of a disulfide bridge linking the N- and C-termini of AtDIR6, and identified two 
potential N-glycosylation sites.[118]  As this disulfide bond may be necessary for proper 
protein folding and stability, the inability of E. coli to form disulfide bonds was likely a 
significant contributor to the difficulty in expressing soluble dirigent proteins.  Shortly 
thereafter, the same group published an optimized expression system for AtDIR6 in 
Pichia pastoris and showed that deglycosylation of the purified protein led to loss of 
dirigent function and aggregation.[117]  Again, the inability of E. coli to perform N-
glycosylation similar to the native organism most likely was a major factor in the 
aggregation of dirigent proteins in our system.  Moreover, the necessity of the N-
glycosylation for dirigent function makes it impossible for a functional dirigent protein to 
be expressed in E. coli.   
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3.3 The potential of a microbial production platform for lignans. 
The original goal of this work was to establish the first step towards a platform for 
lignan biosynthesis in E. coli. Very recently, Kuo et al. published the bioconversion of 
pinoresinol to matairesinol, a precursor to podophyllotoxin in E. coli.[59]  In this study, a 
strain expressing a fusion of two plant enzymes, pinoresinol-lariciresinol reductase and 
secoisolariciresinol reductase (PLR-SDH), was fed exogenous pinoresinol and catalyzed 
its conversion to matairesinol.[59]  An ideal biosynthetic platform for lignans could network 
in vivo stereospecific oxidative radical coupling with the use of downstream biosynthetic 
enzymes.  However, taken together, our findings of the difficulty of dirigent protein 
expression in E. coli combined with the recent studies on the necessity of post-
translational modifications for dirigent function demonstrate the infeasibility of achieving 
stereoselective oxidative radical coupling in a bacterial host.  The establishment of an 
overexpression system for functional dirigent proteins in P. pastoris[117] points to the use 
of eukaryotic microbes as a more suitable heterologous host for lignan biosynthesis.  
Granted that a suitable single electron oxidase could be identified, the P. pastoris 
dirigent protein expression strain could also be equipped with upstream biosynthetic 
enzymes as well as the PLR-SDH fusion created by Kuo et al.[59] for the efficient 
bioconversion of cheap phenolic feedstocks, such as ferulic acid, to valuable lignans, 
such as matairesinol.[117] 
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4. Conclusions 
In order to create a microbial biosynthetic platform for valuable lignan compounds, we 
established the expression in E. coli of two proteins necessary for stereo- and regio-
selective oxidative radical coupling of coniferyl alcohol to (+)-pinoresinol.  The single 
electron oxidase SLAC was successfully expressed, cloned, purified and shown to 
oxidize coniferyl alcohol to pinoresinol both in vitro and in vivo.  The characterized (+)-
pinoresinol-forming dirigent protein FiDRP1 was solubly expressed, after extensive 
expression optimization, but was not found to be functional in E. coli.  Finally, AtDRP5 
was expressed at low levels and shown to have the same propensity as FiDRP1 to 
aggregate.  Studies published during the completion of this work have illustrated the 
infeasibility of using E. coli as a heterologous host for lignan biosynthesis, due to the 
requirement of post-translational modifications for dirigent protein function.  By contrast, 
the use of a eukaryotic microbe, such as P. pastoris, shows much greater promise for 
the achievement of our original goal of microbial conversion of cheap feedstocks to 
value-added lignans. 
5. Materials and Methods 
5.1 Chemicals and Enzymes 
Chemicals for this work were procured as follows: (+)-pinoresinol (Arbo Nova, Turku, 
Finland); coniferyl alcohol, HEPES, MES (Sigma Aldrich, St. Louis, MO, USA); L-(+)-
arabinose (ICN Biomedical, Inc., Aurora, OH, USA); IPTG (G. Biosciences, St. Louis, 
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MO, USA); Tris (Fisher Scientific, Waltham, MA, USA); cupric sulfate pentahydrate 
(Baker Analyzed, Phillipsburg, NJ, USA); potassium acetate, sodium sulfate 
(Mallinckrodt, St. Louis, MO, USA).  The following enzymes and kits were used for DNA 
manipulation and protein visualization according to the manufacturers’ protocols: 
Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA); QIAquick Gel 
Extraction Kit (Qiagen, Hilden, Germany); Taq and Pfu DNA polymerases (Life 
Technologies, Carlsbad, CA, USA); restriction enzymes, T4 DNA ligase (New England 
Biolabs, Ipswich, MA, USA); Monoclonal Mouse IgG1 Anti-poly-His Antibody (R&D 
Systems, Minneapolis, MN, USA); SuperSignal West Pico Mouse IgG Detection Kit 
(Thermo Scientific, Rockford, IL, USA).  Oligomers used for the assembly of the codon-
optimized gene encoding FiDRP1 were obtained from Integrated DNA Technologies 
(Coralville, IA, USA). 
5.2 Strains, Growth Conditions and Expression Studies 
E. coli DH5α and E. coli JM109 were used for all plasmid manipulation and cloning and 
were cultured at 37 °C in Luria-Burtani (LB) broth with ampicillin (100 µg/mL) as needed.  
All protein expression experiments were carried out using E. coli BW27784 (E. coli 
Genetic Stock Center, New Haven, CT), which overexpressed the araE gene encoding 
an arabinose transporter,[119] or E. coli BL21 (DE3), which expresses a T7 RNA 
polymerase.  A list of strains used in this study is listed in Table 2.1.  For the in vivo 
SLAC activity assay, E. coli BW27784 cells transformed with pUCmodRBS-SLAC were 
cultured in modified M9 supplemented with 1.25 g/L yeast extract and 5 g/L glycerol 
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instead of glucose.  For protein expression analysis, 100 mL cultures of cells containing 
overexpression plasmids were grown in LB media at various temperatures as noted in 
the main text and figure captions.  At various timepoints, 5-mL samples of the cultures 
were harvested and cells pelleted for 5 min at 4000 RPM and 4 °C.  The media was 
discarded and cell pellets were resuspended in 1 mL 100 mM Tris pH 8.0 with 10 mM 
NaCL and lysed by 1 min sonication (5 s on, 10 s off).  The lysate was centifuged for 10 
min at 13,200 RPM at and 4 °C; the resulting supernatant was removed and saved, and 
the pellet was resuspended in 1 mL 100 mM Tris pH 8.0 with 10 mM NaCL.  These 
samples were subjected to SDS-PAGE and anti-His-tag western blotting. 
Table 2.1. Strains used in this study. 
 
Strain Description Source 
Escherichia coli DH5α 
fhuA2 lacZ::T7 gene1 [lon] ompT gal 
sulA11 R(mcr-73::miniTn10--Tet
S
)2 [dcm] 
R(zgb-210::Tn10--Tet
S
) endA1 Δ(mcrC-
mrr)114::IS10 
New England 
Biolabs, Ipswich, 
MA, USA 
Escherichia coli JM109 
endA1 glnV44 thi-1 relA1 gyrA96 recA1 
mcrB
+
 Δ(lac-proAB) e14- [F' traD36 
proAB
+
 lacI
q
 lacZΔM15] hsdR17(rK
-
mK
+
) 
New England 
Biolabs, Ipswich, 
MA, USA 
Escherichia coli BW27794 
lacIq rrnB3 DlacZ4787 hsdR514 
DE(araBAD)567 DE(rhaBAD)568 
DE(araFGH) U(DaraEp PCP")±araE) 
[119]
 
Escherichia coli BL21 (DE3) 
F
–
 ompT gal dcm lon hsdSB(rB
-
 mB
-
) 
λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 
nin5]) 
New England 
Biolabs, Ipswich, 
MA, USA 
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5.3 Gene amplification and cloning 
The gene encoding SLAC (GenBank: CAB45586.1) was amplified from Streptomyces 
coelicolor genomic DNA with a forward primer containing an NdeI site at the 5’ end and 
a reverse primer containing an in-frame XhoI site and no stop codon at the 5’ end.  This 
was digested and ligated into pUCmodRBS cut with the same restriction sites, such that 
the C-terminal His-tag contained on the plasmid was in frame with the SLAC open 
reading frame.  A truncated version of the gene encoding FiDRP1 (GenBank: 
AAF25357.1) without the N-terminal 24-residue plant cell wall targeting sequence 
(MVSKTQIVALFLCFLTSTSSATYG) was assembled through overlap extension PCR of 
eight 82-88 nucleotide synthetic DNA oligomers.  The oligomers were mixed in 
equimolar amounts and subjected to PCR using a forward primer containing and NdeI 
site and a reverse primer containing an XhoI site either with or without a stop codon.  
The amplified DNA was digested and ligated into pUCmodRBS cut with the same 
restriction sites.  In the case of the amplicon without the stop codon, the C-terminal His6 
tag contained on the plasmid was in frame with the FiDRP1 open reading frame; in the 
case of the amplicon with the stop codon, the resulting protein remained non-His-tagged.  
Subsequently, pUCmodRBS-FiDRP1 (no His-tag) was digested with NdeI and XhoI, and 
the resulting fragment was ligated into pET15b digested with the same enzymes such 
that the N-terminal His-tag and thrombin cleavage site contained on the plasmid was in 
frame with the FiDRP1 open reading frame.  The putative dirigent proteins from A. 
thaliana, AtDRP2 (GenBank: AEE33205.1; TAIR: AT1G5521), AtDRP3 (GenBank: 
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AEC07124.1; TAIR: AT2G21110) and AtDRP5 (GenBank: AEE34203.1; TAIR: 
AT1G64160), were amplified from cDNA clones obtained from the Arabidopsis Biological 
Resource Center.  Amplification excluded the N-terminal plant cell wall targeting 
sequence for each protein (AtDRP2, MAKLIFFLAVQI; AtDRP3, MGKNLGLVVSFY; 
AtDRP5, MVGQMKSFLFLFVFLV) and was performed with a forward primer containing 
an NdeI site and a reverse primer containing an XhoI site.  The amplified DNA was 
digested and ligated into pUCmodRBS cut with the same restriction sites such that the 
C-terminal His-tag contained on the plasmid was in frame with the gene.  Subsequently, 
using the pUCmodRBS clones as templates, these genes were re-amplified using 
forward primers containing AscI sites and reverse primers containing PacI sites, such 
that the C-terminal His-tag was amplified with the gene.  The amplified DNA was then 
ligated into pBADmod1 digested with the same enzymes.  A list of plasmids used in this 
study is given in Table 2.2. 
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Table 2.2. Plasmids used in this study. 
Plasmid  Description Source 
Standard Plasmid 
Backbones 
  
pUCmodRBS pMB1 (colE1); Amp
r
 PlacP’ 
[120]
 
pET15b 
pBR322; Amp
r
PT7; N-terminal 6xHis-tag 
and thrombin cleavage site (ntH6) 
Novagen (EMD 
Millipore) 
pBADmod1 pMB1 (colE1); Amp
r
 ParaBAD 
[11]
 
Expression Plasmids   
pUCmodRBS-SLAC pUCmodRBS:: PlacP’SLACctH6 This study 
pUCmodRBS-FiDRP1-ctH6 pUCmodRBS:: PlacP’fiDRP1ctH6 This study 
pUCmodRBS-FiDRP1 pUCmodRBS:: PlacP’fiDRP1 This study 
pET15b-FiDRP1 pET15b:: PlacP’fiDRP1 This study 
pUCmodRBS-AtDRP2-ctH6 pUCmodRBS:: PlacP’atDRP2ctH6 This study 
pUCmodRBS-AtDRP3-ctH6 pUCmodRBS:: PlacP’atDRP3ctH6 This study 
pUCmodRBS-AtDRP5-ctH6 pUCmodRBS:: PlacP’atDRP5ctH6 This study 
pBADmod1-AtDRP2-ctH6 pBADmod1:: ParaBADatDRP2ctH6 This study 
pBADmod1-AtDRP3-ctH6 pBADmod1:: ParaBADatDRP3ctH6 This study 
pBADmod1-AtDRP5-ctH6 pBADmod1:: ParaBADatDRP5ctH6 This study 
5.4 HPLC analysis of oxidative radical coupling assays 
Coniferyl alcohol oxidation assays were performed using the conditions described in 
figure legends (Figure 2.2, Figure 2.3, Figure 2.9).  Samples from assays were extracted 
twice in 2x volume ethyl acetate, and the organic fraction was dried to completion and 
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resuspended in methanol for a 10x concentration of the original sample.  For detection of 
coniferyl alcohol and racemic pinoresinol, samples were separated via reverse-phase 
chromatography on a Zorax SB-C18 column (5 uM, 4.6 X 250 mm) with a 1 mL/min flow 
rate using the following timetable: 5% acetonitrile isocratic for 5 min; gradient to 10% 
acetonitrile for 15 min; gradient to 20% acetonitrile for 25 min; gradient to 50% 
acetonitrile for 15 min; post-run at 5% acetonitrile for 10 min.  Buffers (acetonitrile and 
water) contained 3% acetic acid.  Coniferyl alcohol was detected at 264 nm; pinoresinol 
was detected at 280 nm.  Analytical standards were used to confirm peak identity.  For 
subsequent chiral separation of racemic pinoresinol, the fractions were collected from 
retention time 51.5 min to 52.5 min, corresponding to the retention time of pinoresinol.  
The collected fractions were lyophilized, resuspended in methanol, and separated on a 
Chiralcel OD-H chiral column (250 x 4.6 mm) with a flow rate of 0.5 mL/min and an 
isocratic elution with 1:1 hexanes:ethanol.  Pinoresinol was detected at 280 nm, and a 
(+)-pinoresinol standard was used to confirm the identity of the (+) enantiomer peak. 
 
Chapter 3. Design and Creation of a Novel Biosynthetic Pathway 
for Hydroxycinnamic Acid Esters in Escherichia coli 
Summary 
Hydroxycinnamic acid esters (HCEs) are widely-distributed phenylpropanoid-derived 
plant natural products. Rosmarinic acid (RA 7), the most well-known HCE, shows 
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promise as a treatment for cancer and neurological disorders. In contrast to extraction 
from plant material or plant cell culture, a microbial production platform for HCEs could 
provide a sustainable, controlled means of production. Through the overexpression of a 
six-enzyme chimeric bacterial and plant pathway, we show the de novo biosynthesis of 
RA 7 and the related HCE isorinic acid (IA 8) in E. coli. Probing the pathway through 
precursor supplementation showed several potential pathway bottlenecks.  We show 
HCE biosynthesis using three plant RAS orthologs exhibiting different levels of HCE 
biosynthesis, but the same ratio of IA 8 to RA 7 produced. This work serves as a proof of 
concept for a microbial production platform for HCEs using a modular biosynthetic 
approach to access diverse natural and non-natural HCEs.  
 
 
 
*This work was accepted to ChemBioChem and published online on 9 September 
2014.[121]  The manuscript has been adapted here with minor formatting revisions. 
1. Introduction 
Hydroxycinnamic acid esters (HCEs) are a diverse class of phenolic plant natural 
products consisting of a hydroxycinnamoyl moiety, typically caffeic acid 6, conjugated 
with another aromatic molecule, such as phenyllactate, shikimate, or quinate.[23, 46] HCEs 
have received attention recently as potential nutraceutical supplements due to their anti-
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oxidant and anti-inflammatory properties. The most well-known HCE, rosmarinic acid 
(RA 7), is the ester of caffeic acid 6 and 3,4-dihydroxyphenyllactic acid (3,4-DHPL 3), 
and shows promise for a broad range of nutraceutical and pharmaceutical applications 
(Scheme 3.1).[23, 46] Of particular interest is its demonstrated anti-carcinogenic and anti-
tumorogenic activities and utility in cancer prevention and treatment in cell culture [78] and 
animal models.[122-125] Additionally, RA 7 exhibits neuroprotective  [94, 126-128] and 
cognition-enhancing effects [129], and has shown promise for use in the prevention and 
treatment of diverse neurological disorders including Alzheimer’s,[130] Parkinson’s 
disease,[131] depression [132] and post-traumatic stress disorder.[133] 
 Currently, RA 7 and other HCEs are produced primarily by extraction from plant 
tissue, which is a costly endeavor limited by the availability of plant material and the low 
concentration of HCEs in plant tissues. There are scant reports on the total [134-135] and 
chemoenzymatic [136] synthesis of RA 7 and some derivatives;[137-138] however, these 
methods are inefficient for economical commercial production, requiring the use of harsh 
chemicals and giving low yields due to a chiral center in RA 7.  Cell culturing methods 
could provide a lower-cost means of mass-production, and many groups have reported 
high production titers for RA 7 from plant cell cultures.[139-144] However, none of these cell 
culturing methods have yet been applied on an industrial scale, perhaps due to the lack 
of understanding of regulatory networks that cause a decline in RA 7 biosynthesis in 
long-term plant cell culture conditions.[23] By contrast, the development of a microbial 
production platform for RA 7 and other HCEs could allow for a more controlled and 
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stable means of producing these compounds. Additionally, the use of a microbial host 
could allow for a modular production system and, through combinatorial biochemistry, 
could lead to the biosynthesis of novel HCEs with valuable biological activities. 
 In plants, HCE biosynthesis relies on the convergence of two pathways – the 
synthesis of the hydroxycinnamoyl-CoA ester donor substrate and the conjugate 
acceptor substrate, which are subsequently ester-linked by a hydroxycinnamoyl 
transferase (Scheme 3.1). In the RA 7 biosynthetic pathway, which has been completely 
elucidated in plants, the hydroxycinnamoyl transferase rosmarinic acid synthase (RAS) 
conjugates 4-hydroxyphenyllactic acid (4-HPL 2) and p-coumaroyl-CoA, and the 
resulting ester is then hydroxylated at the 3 and 3’ positions by cytochrome P450s to 
give RA 7.[46, 145]  The native plant biosynthetic pathway for RA 7 is impractical for use in 
a microbial host, requiring the co-overexpression of several plant enzymes including 
microsomal cytochrome P450s.  Because they require localization to the endoplasmic 
reticulum for optimal activity and an associated NADPH-cytochrome P450 reductase for 
electron transfer, plant microsomal P450 expression is notoriously problematic in 
microorganisms commonly used in biotechnology, such as E. coli and S. cerevisiae.[34] 
Fortunately, however, many hydroxycinnamoyl transferases, including the three RASs 
previously characterized, show broad substrate flexibility and readily accept 3,4-
hydroxylated acids and CoA esters as substrates.[146-155] This could allow for the design 
of a biosynthetic pathway in which the 3-hydroxylation of the donor and acceptor 
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substrate precursors could be carried out by a non-cytochrome P450 bacterial 
monooxygenase prior to ester formation.  
 Recent studies have reported the bioconversion of phenolic precursors to 
hydroxycinnamoyl amides,[52-53] shikimates and quinates [51] and the biosynthesis of 
hydroxycinnamoyl anthranilates from glucose [54] in E. coli. In this study, we designed 
and constructed a novel, modular biosynthetic pathway for the biosynthesis of RA 7 from 
endogenous L-tyrosine and 4-hydroxyphenylpyruvate (4-HPP 1) (Scheme 3.1).  Through 
the overexpression of this engineered pathway, we observe de novo biosynthesis of RA 
7 and isorinic acid (IA 8), another hydroxycinnamoyl-hydroxyphenyllactate conjugate, in 
E. coli using three orthologous RAS enzymes. This work serves as a proof of concept for 
a microbial production platform for RA 7 and other HCEs. Advances in metabolic 
engineering of the shikimate pathway in E. coli have shown the utility of this approach for 
the mass production of aromatic compounds from simple feedstocks.[16, 49, 61, 63, 67, 156] 
This pathway, used in a tyrosine-overproducing strain and with future optimization of 
pathway enzyme activity and expression, could lead to an inexpensive production 
platform for HCEs. 
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2. Results and Discussion 
2.1 Design of a chimeric RA biosynthetic pathway for E. coli 
In order to design an effective system for microbial production of RA 7 and minimize the 
number of plant enzymes required, we designed a novel chimeric bacterial-plant 
 
Scheme 3.1. Redesigned chimeric RA biosynthetic pathway. The D-hydroxyisocaproate 
dehydrogenase HdhA from L. delbrueckii subsp. bulgaricus catalyzes the conversion of 
endogenous 4-HPP 1 to 4-HPL 2, which is subsequently meta-hydroxylated by hydroxylase 
complex HpaBC cloned from E. coli to yield 3,4-DHPL 3, the intended acceptor substrate for 
rosmarinic acid synthase (RAS). Donor substrate biosynthesis is achieved through the 
conversion of L-tyrosine 4 to p-coumaric acid by a tyrosine ammonia lyase from R. 
sphaeroides (RsTAL) and hydroxylation of p-coumaric acid 5 to caffeic acid 6 by HpaBC. A 
4-coumaroyl-CoA ligase from Arabidopsis thaliana (At4CL2) generates the CoA-ester of the 
donor substrate, allowing ester formation catalyzed by RAS. Both 3,4-DHPL  3 and 4-HPL 2 
may be accepted by RAS to form both RA 7 and IA 8, respectively. 
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pathway in which the meta-hydroxylation of the donor and acceptor substrates takes 
place before condensation by RAS (Scheme 3.1). In this pathway, caffeic acid 6 and 3,4-
DHPL  3 serve as the donor and acceptor substrates, respectively, rather than p-
coumaric acid 5 and 4-HPL 2 as in the plant pathway. All pathway genes were initially 
cloned into pUCBB, one of our group’s custom set of BioBrick™-compatible vectors, for 
subsequent assembly of multi-gene plasmids to create the biosynthetic pathway 
modules described later.[157]  Monocistronic “bricks” containing gene expression 
cassettes allow for “stacking” using the standard BioBrick™ restriction sites [158] that can 
be reused repeatedly. 
 The biosynthesis of caffeic acid 6 has been demonstrated previously in E. coli;[47-
50, 54] however, at the time of this work, biosynthesis of 3,4-DHPL 3 had not been shown 
in E. coli. To achieve 3,4-DHPL 3 biosynthesis, we first chose a  2-hydroxyacid 
dehydrogenase from Lactobacillus delbrueckii subsp.bulgarcius, HdhA, that was 
originally characterized as a D-isomer specific 2-hydroxyisocaproate dehydrogenase 
and was shown to have some activity against phenylpyruvic acid.[159] We hypothesized 
that the overexpression of the gene hdhA would lead to the reduction of endogenous 4-
HPP 1 to 4-HPL 2 as a first step in 3,4-DHPL 3 biosynthesis (Scheme 3.1). Therefore, 
we amplified the gene encoding HdhA from L. delbrueckii genomic DNA and created the 
plasmid pUCBB-hdhA, which contains a constitutive expression cassette for hdhA 
(Figure 3.1). E. coli BW27784 transformed with pUCBB-hdhA were cultured in minimal 
media and samples were taken over time, cleared of cells, and extracted with ethyl 
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acetate for HPLC analysis. We observed production of 4-HPL 2 to 39 ± 6 mg/L without 
the addition of any precursors to the culture media (Figure 3.2), suggesting that that 
HdhA reduces endogenous 4-HPP 1 to 4-HPL 2.  No 4-HPL 2 biosynthesis was 
observed in transformants of the empty pUCBB plasmid.   
 
 
Figure 3.1. Plasmids assembled for donor substrate, acceptor substrate and HCE 
biosynthesis. All plasmids were assembled using the BioBrick™ system previously 
designed and built by our lab.
[155]
 Plac’, a modified constitutive lac promoter; ParaBAD, 
arabinose inducible promoter; araC, gene encoding the repressor of ParaBAD; pUCBB, high 
copy number plasmid backbone; pCDFBB, medium copy number plasmid backbone; 
pACBB, low copy number plasmid backbone. Plasmids that constitute the functional three-
module RA 7 biosynthetic pathway are boxed. 
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 The next challenge in 3,4-DHPL 3 biosynthesis was the meta-hydroxylation of 4-
HPL 2 to 3,4-DHPL 3 (Scheme 3.1). Two flavin-dependent monooxygenases, Sam5 
from Saccharothrix espanaensis and the E. coli 4-hydroxyphenylacetate 3-hydroxylase 
complex, HpaBC, have been shown to carry out the meta-hydroxylation of p-coumaric 
acid 5 and facilitate biosynthesis of caffeic acid 6 in E. coli when co-overexpressed with 
a tyrosine ammonia lyase (TAL).[47-50] Due to the similarity in structure between p-
coumaric acid 5 and 4-HPL 2, we hypothesized that one of these two monooxygenases 
may be able to accept 4-HPL 2 as a substrate and produce 3,4-DHPL 3. We amplified 
 
Figure 3.2. De novo biosynthesis of 4-HPL by E. coli BW27784 cells transformed with 
pUCBB-hdhA. Transformants were cultured in minimal media at 30 °C; culture samples 
were taken over time, cleared of cells, and extracted with ethyl acetate for HPLC analysis. 
An analytical standard of 4-HPL 2 was used to confirm peak identity and quantification. No 4-
HPL 2 was detected in cultures of cells transformed with the empty pUCBB vector. 
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the gene encoding Sam5 from S. espanaensis genomic DNA, amplified the genes 
encoding HpaB and HpaC individually from E. coli BL21 genomic DNA, and created the 
constitutive overexpression plasmids pUCBB-sam5 and pUCBB-hpaBC (Figure 3.1). E. 
coli BW27784 transformed with pUCBB-hpaBC were cultured in minimal media in the 
presence of 1 mM p-coumaric acid 5 or 1 mM 4-HPL 2 (Scheme 3.1); culture samples 
were taken over time, cleared of cells, extracted and analyzed via HPLC. The 
overexpression of sam5 led to the complete conversion of p-coumaric acid 5 to caffeic 
acid 6 within 24 h, as had been shown previously; however, no conversion of 4-HPL 2 to 
3,4-DHPL 3 could be observed. By contrast, the overexpression of hpaBC led to the 
complete conversion of p-coumaric acid 5 to caffeic acid 6 within 24 h and the detection 
of 3,4-DHPL 3 after 24 h (Figure 3.3). Additionally, because we chose to employ the 
same enzyme to carry out two simultaneous conversions in the RA biosynthetic 
pathway, we incubated transformants of pUCBB-hpaBC with both 1 mM 4-HPL 2 and 1 
mM p-coumaric acid 5 to determine if the presence of one substrate would inhibit the 
activity of the enzyme against the other.  We did not observe any significant effect of 
feeding both substrates simultaneously on enzyme activity with either substrate (Figure 
3.S1).  We therefore decided to use HpaBC for the meta-hydroxylation of 4-HPL 2 as 
well as for caffeic acid 6 biosynthesis. 
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Figure 3.3. Bioconversion of p-coumaric acid and 4-HPL to caffeic acid and 3,4-
DHPL, respectively, by E. coli BW27784 transformants of pUCBB-hpaBC. 
Transformants were cultured in minimal media at 30 °C, supplemented with 1 mM p-
coumaric acid or 1 mM 4-HPL 2 culture and samples were taken over time and processed 
for HPLC analysis. Samples were compared to standard compounds in order to identify 
compound peaks. Solid trace, pUCBB-hpaBC transformants; dotted trace, empty pUCBB 
transformants (control). 
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After confirming the activities of HdhA and HpaBC with 4-HPP 1 and 4-HPL 2, 
respectively, as key RA 7 precursors, we cloned genes encoding enzymes with known 
activities for the remaining steps of the chimeric pathway as shown in Scheme 3.1.  In 
our chimeric pathway design, acceptor substrate biosynthesis combines the activities of 
HdhA and HpaBC for the production of 3,4-DHPL 3. For donor substrate biosynthesis, 
we chose a highly active TAL from Rhodobacter sphaeroides (RsTAL) that we have 
previously shown to convert L-tyrosine into p-coumaric acid 5.[11] RsTAL and HpaBC 
together catalyze the conversion of endogenous L-tyrosine 4 to caffeic acid 6. For CoA 
activation of the donor substrate caffeic acid 6, we selected 4-coumarate-CoA ligase 2 
from Arabidopsis thaliana (At4CL2) due to the reported preference of this isoenzyme for 
caffeic acid 6 as a substrate [160] and cloned the gene from A. thaliana cDNA. Finally, to 
carry out the condensation of 3,4-DHPL 3 and caffeic acid 6 to form RA 7, we chose the 
first characterized RAS from Coleus blumei (CbRAS) [153, 161] and cloned the gene from 
cDNA synthesized from RNA extracted from C. blumei plant tissue.  
2.3 De novo biosynthesis of RA and IA using a modular biosynthetic pathway 
One of the biggest advantages of using a heterologous system for the assembly and 
expression of biosynthetic pathways is the relative ease with which pathway design and 
precursor input can be manipulated once a working pathway has been established. The 
biosynthesis of HCEs lends itself well to combinatorial biochemistry, because the 
hydroxycinnamoyl transferases that carry out condensation of the donor and acceptor 
substrates have been shown to have relatively broad substrate specificity and catalyze 
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the condensation of a range of esters and amides [152-154]. The construction of a modular 
HCE biosynthetic pathway would therefore allow for the interchange of modules for the 
biosynthesis of different acceptor and donor substrates and the condensation of these to 
synthesize a range of known or novel HCEs. To this end, we assembled and tested 
three modular plasmid systems for the production of RA 7 (Figure 3.1) using our 
previously designed, compatible BioBrick™ plasmids for pathway assembly in E. coli.[157] 
 Because the conversion of 4-HPL 2 to 3,4-DHPL 3 by HpaBC appeared to be 
relatively slow (Figure 3.3), we assembled the genes for 3,4-DHPL 3 biosynthesis onto 
the high copy number vector pUCBB. We first attempted a two-plasmid pathway setup 
that consisted of 3,4-DHPL 3 (acceptor substrate) biosynthetic genes and cbRAS being 
expressed on the plasmid pUCBB-ABCR and the donor substrate biosynthetic genes on 
the lower-copy plasmids pCDFBB-TBC4 or pACBB-TBC4 (Figure 3.1). Because we 
have found co-expression of 4CL enzymes with TALs to be problematic, perhaps due to 
the depletion of CoA pools within the cell, at4CL2 was expressed under the control of an 
arabinose inducible promoter (ParaBAD) while all other genes were expressed 
constitutively from a modified Plac’ promoter.
[157] When E. coli BW27784 was co-
transformed with the acceptor substrate and cbRAS plasmid pUCBB-ABCR and the 
donor substrate plasmids pCDFBB-TBC4 or pACBB-TBC4 and expression of at4CL2 
was induced 24 h after inoculation, no RA 7 could be detected in the media. 
 Next, we assembled a three-plasmid modular system, consisting of the acceptor 
substrate module pUCBB-ABC, containing hdhA and hpaBC; the donor substrate 
 69 
 
module pCDFBB-TBC, containing rsTAL and hpaBC; and the hydroxycinnamoyl transfer 
module, pACBB-4cbR, containing at4CL2 and cbRAS (Figure 3.1). Because 3,4-DHPL 3 
production by HpaBC was first seen 24 h after the addition of 4-HPL 2 (Figure 3.3), in 
this three-module system we expressed both at4CL2 and cbRAS under the control of the 
arabinose inducible promoter ParaBAD, while all other genes were expressed constitutively 
from Plac’. Transformants harboring these three plasmids were grown in minimal media, 
and at4CL2 and cbRAS expression was induced 24 h after inoculation. This led to the 
detection of RA 7 in the culture media 48 h after induction and up to 0.33 ± 0.05 μM RA 
7 72 h after the induction of at4CL2 and cbRAS expression (Figure 3.4). E. coli cells 
harboring pUCBB-ABC, pCDFBB-TBC and empty pACBB or all three empty plasmid 
backbones were tested as negative controls; no RA 7 biosynthesis was observed in 
these cultures.  We were concerned that replicating three plasmids may put an 
unnecessary metabolic burden on the E. coli cells and that expressing hpaBC at high 
levels from both pUCBB and pCDFBB may overwhelm the host’s protein folding 
machinery and lead to aggregation of insoluble recombinant proteins in the cell.  
Therefore, we attempted one non-modular plasmid, pUCBB-TABC4R, with cbRAS and 
at4CL2 under the control of the arabinose promoter and rsTAL, hdhA and hpaBC 
expressed constitutively (Figure 3.1). When transformants of this plasmid were grown in 
minimal media and at4CL2 and cbRAS expression was induced 24 h after inoculation, 
no production of RA 7 was detected.  
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 Extracts of culture media of cells expressing the three-plasmid pathway also 
contained an HPLC peak with a different retention time from RA 7 but a nearly identical 
UV spectrum (Figure 3.S2). Analysis via LCMS revealed this peak to be IA 8, the ester 
 
Figure 3.4. De novo biosynthesis of HCEs in E. coli. E. coli BW27784 was co-transformed 
with pUCBB-ABC containing the acceptor substrate module, pCDFBB-TBC4 containing the 
acceptor substrate module, and pACBB-4cbR containing the hydroxycinnamoyl transfer 
module (Figure 1). Transformants were cultured in minimal media at 30 °C, and at4CL2 and 
cbRAS expression was induced after 24 h growth. Culture samples were taken over time and 
processed for HPLC and LC-MS analysis. An analytical standard of RA 7 was used to confirm 
peak identity and mass fragmentation of RA 7, and MS/MS mass spectra confirm the 
presence of both RA 7 and IA 8 in culture media. Asterisks denote key mass fragments in the 
identification of the acceptor substrate moieties of the products. 
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of 4-HPL 2 and caffeic acid 6, based on mass shift of the  fragment corresponding to 
3,4-DHPL 3 from 197 to 181 m/z, and the mass fragment corresponding to caffeic acid 6 
(161 m/z) remaining the same (Figure 3.4). The biosynthesis of IA 8 alongside RA 7 can 
be explained by the previously reported slight preference of CbRAS to bind 4-HPL 2 
over 3,4-DHPL 3 [153] and the apparently slow turnover of 4-HPL 2 to 3,4-DHPL 3 by 
HpaBC (Figure 3.3). 
2.4 Feeding cultures with pathway precursors shows potential bottlenecks and a 
loss of acceptor substrates 
Because of the relatively low concentration of HCEs produced and the detection of both 
RA 7 and IA 8 in the media, we fed the E. coli cells expressing the engineered RA 7 
pathway modules selected precursors and intermediates and measured the impact on 
HCE production in order to gain insight into potential pathway bottlenecks. Cultures of E. 
coli BW27784 harboring all three RA 7 pathway modules (pUCBB-ABC, pCDFBB-TBC 
and pACBB-4cbR) were supplemented with either 1 mM L-tyrosine 4, 1 mM p-coumaric 
acid 5, 1 mM caffeic acid 6, or 1 mM caffeic acid 6 and 1 mM 4-HPL 2 24 h after 
inoculation and at the same time of induction of at4CL2 and cbRAS expression, and the 
levels of HCEs and pathway intermediates were measured via HPLC 48 h after induction 
(Figure 3.5A).  
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Figure 3.5. Limiting factors 
and leaks in the E. coli 
HCE biosynthetic pathway. 
E. coli BW27784 containing 
the modular HCE 
biosynthesis plasmids were 
cultured in minimal media at 
30 °C; after 24h, at4CL2 and 
cbRAS expression was 
induced and various 
supplements were added to 
a final concentration of 1 
mM. Culture samples were 
taken over time and analyzed 
by HPLC. Asterisks denote 
significantly different 
concentrations at p ˂ 0.05. A) 
HCE production is increased 
in the presence of different 
feeding precursors 48h after 
induction of at4CL2 and 
cbRAS. B) The total 
concentrations of donor 
substrates and HCE products 
remain stable over time. C) 
The total concentrations of 
acceptor substrates and HCE 
products significantly 
decreases after 24 h. 
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The addition of 1 mM L-tyrosine 4 yielded a significant increase in both RA 7 and 
IA 8 production (p ˂ 0.001), suggesting that precursor availability is a significant 
bottleneck to the productivity of this pathway. Additionally, supplementing 1 mM p-
coumaric acid 5 or 1 mM caffeic acid 6 resulted in a further increase in RA 7 production 
(p ˂ 0.05), but only 1 mM caffeic acid 6 led to a significantly greater increase in IA 8 
biosynthesis than feeding of 1 mM L-tyrosine (p ˂ 0.01). These results suggest that, 
while the availability of L-tyrosine is a limiting factor in the donor substrate biosynthetic 
pathway, the conversion of L-tyrosine to p-coumarate by RsTAL is also a bottleneck, as 
has been shown in several other engineered hydroxycinnamic acid biosynthetic 
pathways.[48-50, 54] 
 Supplementation of 1 mM caffeic acid 6 and 1 mM 4-HPL 2 led to significantly 
higher RA 7 and IA 8 biosynthesis than any of the other added pathway intermediates (p 
˂ 0.05), suggesting that acceptor substrate availability and therefore the conversion of 4-
HPP 1 to 4-HPL 2 by HdhA may also be a limiting factor. Interestingly, none of the 
supplemented cultures showed a significant difference in the ratio of IA 8 to RA 7 
compared to the unfed culture, except when 1 mM caffeic acid 6 and 1 mM 4-HPL 2 
were added, which increased the ratio of IA 8 to RA 7 10-fold (Table 3.S1).  This 
increase in the ratio of IA 8 to RA 7 due to the addition of 4-HPL 2 illustrates the 
potential of this or related HCE biosynthetic pathways to be pushed toward production of 
the desired product by the addition of pathway precursors. 
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 In order to investigate in more detail the flux through the donor and acceptor 
substrate branches of the engineered RA 7 pathway, we measured the concentrations of 
pathway intermediates when supplementing cultures with donor or acceptor substrates 
and precursors over time. When 1 mM caffeic acid 6 and 1 mM 4-HPL 2 were added to 
cultures, the sum of the molar concentrations of p-coumaric acid 5, caffeic acid 6 and 
HCE products remained stable over time (Figure 3.5B). By contrast, the sum of the 
molar concentrations of acceptor substrates (4-HPL 2 and 3,4-DHPL 3) and HCE 
products decreased significantly within the first 24 h (Figure 3.5C). This suggests that a 
leak exists in the acceptor substrate biosynthetic pathway. One possible explanation is 
that acceptor substrates are being lost to polyphenol formation. Melanin production has 
been well-documented in E. coli through the overexpression of tyrosinase enzymes 
which catalyze the 3-hydroxylatioin of L-tyrosine 4 to L-DOPA and dopaquinone.[162] 
Indeed, we observe the accumulation of a dark brown pigment on agar plates or liquid 
cultures of cells overexpressing hpaBC (Figure 3.S3), presumably due to the conversion 
of endogenous L-tyrosine 4 to L-DOPA.[50, 163-164] Similarly, 3,4-DHPL 3 may be further 
oxidized to 3,4-dihydroxyphenyllactoquinone, non-enzymatically polymerized to a 
polyphenol and thus removed from the precursor pool of the HCE biosynthetic pathway. 
2.5 Three orthologous RASs give different levels of RA and IA production, but a 
consistent ratio of IA to RA 
Because of the low concentration of HCEs detected in the media and the detection of a 
high ratio of IA 8 to RA 7 in the media, we sought to compare the in vivo activity and 
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product profile of CbRAS with other RAS orthologs. The DNA encoding two other 
characterized RAS genes, from Lavandula angustifolia (laRAS) [152] and Melissa 
officinalis (moRAS),[154] was synthesized based on their respective cDNA sequences, 
and the genes were assembled into the hydroxycinnamoyl transfer module of the HCE 
biosynthetic pathway, giving pACBB-4laR and pACBB-4moR (Figure 3.1). E. coli 
BW27784 were transformed with pUCBB-ABC, pCDFB-TBC and either pACBB-4cbR, 
pACBB-4laR, pACBB-4moR or empty pACBB as a control,[157] transformants were 
cultured in minimal media, and at4CL2 and RAS-encoding gene expression was induced 
24 h after inoculation. At 72 h after induction, there was a significant difference in the 
concentrations of RA 7 and IA 8 detected with the three different RAS enzymes (Figure 
3.6): LaRAS led to significantly higher HCE production than CbRAS (p ˂ 0.05), up to 0.9 
± 0.2 µM RA 7 and 3.2 ± 0.4 µM IA 8 in the media; MoRAS led to significantly higher 
production than both LaRAS and CbRAS (p ˂ 0.05), up to 1.8 ± 0.3 µM RA 7 and 5.3 ± 
0.7 µM IA 8 in the media.  An expression study of these enzymes did not show a 
difference in protein levels that correlated with HCE production, suggesting that the 
difference in HCE production levels may be due to differences in catalytic activity rather 
than expression (Figure 3.S4).  Interestingly, the ratio of IA 8 to RA 7 detected did not 
significantly differ between orthologs (p ≥ 0.2); the average ratio of IA 8 to RA 7 in all 
samples was 4.0 ± 0.8 (Table 3.S2).  The lack of characterized RAS genes that favor 
production of RA 7 over IA 8 suggests that an enzyme engineering approach would be 
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necessary to increase RAS substrate specificity toward 3,4-DHPL 3 and thus direct the 
pathway flux toward the RA 7 product. 
3. Conclusions 
In this work, we have successfully designed a chimeric biosynthetic pathway tailored for 
a microbial host that allows heterologous production of the plant-specific HCEs, RA 7 
 
Figure 3.6. HCE biosynthesis in E. coli cultures expressing three orthologous RAS 
enzymes in the context of the redesigned biosynthetic pathway. Two new 
hydroxycinnamoyl transfer module plasmids were constructed containing laRAS and 
moRAS. E. coli BW27784 were co-transformed with empty pACBB, pACBB-4cbR, pACBB-
4laR or pACBB-4moR, pUCBB-ABC and pCDFBB-TBC and analyzed for HCE production 72 
h after induction of the at4CL2 and RAS-encoding genes. Asterisks denote significantly 
different concentrations at p ˂ 0.01.  
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and IA 8. To accomplish this, we implemented bacterial enzymes with known 
biosynthetic utility for hydroxycinnamic acid production, identified new substrates for 
known bacterial enzymes to establish 4-HPL 2 and 3,4-DHPL 3 biosynthesis in E. coli, 
and incorporated the plant enzymes At4CL2 and RAS to carry out hydroxycinnamoyl 
transfer.  Incorporation of three plant RAS orthologs showed a significant variation in 
overall HCE biosynthesis, but not in the product profile of the HCEs observed, which 
remained about 4:1 IA 8 to RA 7 for all three RASs. E. coli cultures expressing the RA 7 
pathway containing the RAS from M. officinalis produced the highest levels of HCEs 
without precursor supplementation, up to 1.8 ± 0.3 µM RA 7 and 5.3 ± 0.7 µM IA 8.  
Because of the modular pathway design, the RA 7 pathway could easily be altered for 
the biosynthesis of different HCEs through swapping the donor substrate, acceptor 
substrate and/or the hydroxycinnamoyl transfer modules. Feeding of alternative 
precursor compounds likewise would allow biosynthesis of structurally diverse HCEs; 
their economic production, however, would depend on access to inexpensive precursor 
sources.  For example, 4-HPL 2 and 3,4-DHPL 3 are infeasible feeding precursors for 
industrial applications given their cost (about $370/g and $1850/g, respectively). 
 Although we achieved RA 7 and IA 8 biosynthesis, the current production levels 
are far less than sufficient for industrial application. One potential means of optimizing 
the HCE biosynthetic pathway would be to increase flux through the shikimate and L-
tyrosine biosynthetic pathways of the host strain. Indeed, the levels of HCEs we observe 
are comparable to previously reported levels of the hydroxycinnamic acid amide 
 78 
 
avenanthramide D produced from glucose in E. coli prior to optimizing L-tyrosine and 
shikimate pathway flux.[54] In that work, a more than 100 fold increase in avenanthramide 
D production was achieved through co-overexpression of rate-limiting enzymes and 
feedback-resistant mutant enzymes to increase flux and decrease feedback inhibition of 
the shikimate and L-tyrosine pathways.[54] Introduction of our engineered HCE pathway 
into a tyrosine- or shikimate-overproducing strain would likely have a similar effect on 
production levels.  
 During the completion of this work, Yao et al. showed the production of 3,4-DHPL 
3 (also known as salvianic acid A or danshensu) in E. coli through the overexpression of 
a mutant D-lactate dehydrogenase from Lactobacillus pentosus and HpaBC.[165] The key 
mutations they used had been shown previously to convert the enzyme from a D-lactate 
dehydrogenase to a D-hydroxyisocaproate dehydrogenase [166] and increase activity 
against phenylpyruvic acid.[167] While Yao et al. do not report on the level of de novo 
production of 4-HPL 2 or 3,4-DHPL 3 without precursor feeding or engineering of 
upstream pathways for L-tyrosine overproduction, they were able to show up to 7.1 g/L 
3,4-DHPL 3 with their tyrosine-overproducing strain in a batch-fed process.[165] The 
implementation of our 3,4-DHPL 3 biosynthetic pathway in a tyrosine-overproducing 
strain could therefore lead to similarly high titers of 3,4-DHPL 3. 
 Several downstream pathway steps are also prime targets for optimization, such 
as TAL activity, which has been shown before to limit E. coli hydroxycinnamic acid 
biosynthetic pathways.[48-50, 54] Another optimization strategy must address the problem 
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of acceptor substrate diversion. This could be achieved by co-localization of the acceptor 
substrate biosynthetic pathway and the RAS, which has proved to be a successful 
strategy to increase the flux through heterologous biosynthetic pathways.[77] Besides an 
increase in production levels, the ability to eliminate byproducts and tune the engineered 
pathway towards the biosynthesis of RA 7 alone, rather than RA 7 and IA 8, would 
increase the value of this pathway. For example, the ratio of RA 7 to IA 8 could be 
increased either by increasing the catalytic efficiency of 4-HPL 2 hydroxylation to 3,4-
DHPL 3 and thus decreasing the pool of 4-HPL 2 in the cell or by altering a RAS to more 
specifically bind 3,4-DHPL 3. In summary, given the numerous options for pathway 
optimization, this work provides the basis for the development of a valuable microbial 
production platform for RA 7 and other HCEs.  
4. Experimental Section 
4.1 Chemicals and Enzymes 
Chemicals used in this study were procured as follows: L-tyrosine 4, caffeic acid 6, 4-
hydroxyphenylpyruvic acid 1, DL-4-hydroxyphenyllactic acid, rosmarinic acid 7 (Sigma 
Aldrich, St. Louis, MO, USA), p-coumaric acid 5 (MP Biomedical, LLC, Solon, OH, USA), 
sodium danshensu (3,4-dihydroxyphenyllactic acid, Select Chemicals, Houston, TX, 
USA), L-(+)-arabinose (ICN Biomedical, Inc., Aurora, OH, USA). The following enzymes 
and kits were used for DNA manipulation according to the manufacturers’ protocols: 
Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA), RNeasy Plant 
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Mini Kit (Qiagen, Hilden, Germany), SuperScript® III Reverse Transcriptase, Zero 
Blunt® TOPO® PCR Cloning Kit, (Life Technologies, Carlsbad, CA, USA), restriction 
enzymes, T4 DNA ligase, Phusion® High Fidelity DNA Polymerase (New England 
Biolabs, Ipswich, MA, USA). 
4.2 Strains, Media and Growth Conditions 
E. coli C2566 (New England Biolabs, Ipswich, MA, USA) was used for plasmid 
manipulation and propagation and was cultivated in Luria-Bertani (LB) medium at 37 °C. 
L. delbrueckii subsp. bulgaricus (DSM-20081) was cultivated anaerobically in MRS broth 
(DSMZ Medium 11) at 37 °C. S. espanaensis (DSM-44229) was cultivated on GYM agar 
plates (DSMZ Medium 65) at 28 °C. All biosynthesis experiments were carried using E. 
coli BW27784 (E. coli Genetic Stock Center, New Haven, CT). [119] Strains used in this 
study are listed in Table 3.S3. 
 For production experiments, seed cultures of E. coli BW27784 containing 
pathway plasmids were cultivated from single colonies overnight and grown in LB media 
at 37 °C with the appropriate antibiotics: ampicillin (100 µg/mL), chloramphenicol (50 
µg/mL), and/or streptomycin (50 µg/mL). After overnight growth these seed cultures 
were used to inoculate cultures in modified M9 media containing yeast extract (1.25 g/L) 
and glycerol (5 g/L) instead of glucose and supplemented with the appropriate 
antibiotics. For cultures to test the biosynthesis of 4-HPL 2, the bioconversion of p-
coumaric acid 5 and 4-HPL 2 to caffeic acid 6 and 3,4-DHPL 3, and the relative 
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expression levels of three RAS orthologs, flasks cultures (100 mL) were inoculated with 
the seed culture (1 mL); for all other experiments, test tube cultures (10 mL) were 
inoculated with the seed culture (100 µL). Where appropriate, the expression of at4CL2 
and RAS-encoding genes was induced 24 h after culture inoculation by the addition of 
arabinose to a final concentration of 0.2 %w/v. For precursor supplementation 
experiments, p-coumaric acid 5, caffeic acid 6, or caffeic acid 6 plus 4-HPL 2 (50 µL 
each) were added to the cultures from 200 mM stocks in methanol to a final 
concentration of 1 mM after 24 h at the same time as induction; L-tyrosine was added to 
a final concentration of 1 mM by the addition of dry powder (2 mg) at the time of 
induction. All biosynthesis experiments were carried out in three biological replicates. 
4.3 Gene Cloning, Plasmid Construction and Enzyme Expression 
All gene cloning and pathway assembly was carried out using our custom set of 
BioBrick™-compatible vectors [157] which are available from Addgene 
(www.addgene.org). The open reading frame (ORF) encoding cbRAS (GenBank: 
CAK55166.1) was amplified from C. blumei cDNA, which was synthesized from RNA 
extracted from plant tissue donated by the University of Minnesota Horticulture Club. An 
ORF encoding At4CL2 (GenBank: AAD47192.1) was amplified from A. thaliana cDNA 
which was a generous gift from the Olszewski laboratory at the University of Minnesota. 
The gene encoding D-2-hydroxyisocaproate dehydrogenase HdhA (GenBank: 
CAI97812.1) was amplified from L. delbrueckii subsp. bulgaricus genomic DNA in two 
pieces using mutagenic primers designed to remove an EcoRI site in the ORF. The 
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resulting PCR products were amplified in an overlap-extension PCR to give the full-
length sequence with a silent mutation eliminating the EcoRI site. The gene encoding 
Sam5 (GenBank: CCH33123.1) was amplified from S. espanaensis genomic DNA. The 
genes encoding HpaB (GenBank: CAQ34705.1) and HpaC (GenBank: AAZ90964.1) 
were amplified individually from E. coli BL21 (DE3) genomic DNA. The gene encoding  
RsTAL from R. sphaeroides (GenBank: ABA81174.1) was amplified from pUC-TAL [11] in 
two pieces with mutagenic primers to remove the EcoRI site, as described above for 
HdhA. ORFs encoding LaRAS (GenBank: ABI48360.1) and MoRAS (GenBank: 
CBW35684.1) were synthesized with their native codon usage (Life Technologies, 
Carlsbad, CA, USA). All genes were amplified with forward primers containing either a 
BglII or a NdeI site at the 5’ end, and a reverse primer containing either an NsiI or NotI 
site and a stop codon at the 5’ end. The genes for At4CL2 and CbRAS were first TOPO-
cloned using the Zero Blunt® TOPO® PCR Cloning Kit according to the manufacturer’s 
protocol. Plasmids TOPO-cbRAS and TOPO-4CL2 were used for future sub-cloning into 
pUCBB. All other amplified genes were digested with the appropriate restriction 
enzymes and ligated into pUCBB digested with the same enzymes. The resulting 
pUCBB-gene plasmids were used for subsequent subcloning and pathway assembly. 
Full primer sequences are listed in Table 3.S4. 
 An initial screen of at4CL2 and cbRAS expression did not show visible 
expression on an SDS-PAGE gel (Figure 3.S5A). Therefore, an N-terminal His-tag was 
added to each of these enzymes by amplification of the genes with forward primers 
 83 
 
containing NdeI sites and the reverse primers containing NotI sites and subsequent 
digestion and cloning into pUCBB-ntH6 [157], which encodes a His-tag and thrombin 
cleavage site just upstream of the NdeI site. Subsequent expression studies showed that 
N-terminally His-tagged At4CL2 protein was visible via SDS-PAGE (Figure 3.S5B). 
Additionally, an anti-His-tag Western blot showed the presence of both N-terminally-His-
tagged At4CL2 and CbRAS (Figure 3.S5C). Because of the apparent increase in At4CL2 
protein levels and the confirmed presence of CbRAS protein, the N-terminally-tagged 
versions of at4CL2 and cbRAS were used for all subsequent subcloning and cultivations. 
Additionally, laRAS and moRAS were cloned into pUCBB-ntH6 before further 
subcloning, such that all RAS enzymes tested carried the same N-terminal His-tag.  
 The assembly of plasmids containing multiple enzymes was carried out via the 
BioBrick™ prefix-stacking strategy as described in [157]. Briefly, for example, after cloning 
hpaB and hpaC individually into the pUCBB backbone, giving pUCBB-hpaB and pUCBB-
hpaC; pUCBB-hpaC was then digested with EcoRI and XbaI, while pUCBB-hpaB was 
digested with EcoRI and SpeI. The resulting DNA fragment containing the modified 
constitutive lac promoter Plac’, 
[157] the ribosome binding site and the hpaB ORF was 
subsequently ligated into the digested pUCBB-hpaC, to give pUCBB-hpaBC, a plasmid 
containing a BioBrick™ comprised of a distinct expression cassette for each gene. All 
plasmids containing multiple genes were constructed in this way by prefix-stacking of the 
appropriate cassette into the appropriate plasmid with the pUCBB backbone. Once the 
multi-enzyme BioBrick™ was constructed in the pUCBB backbone, if needed, it was 
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subsequently moved to the pACBB or pCDFBB backbones [157] through digestion with 
EcoRI and SpeI and ligation to the desired backbone digested with the same enzymes. 
A list of plasmids created for this study and their descriptions is given in Table 3.S5. 
4.4 HPLC and LC-MS Analysis of Pathway Intermediates and Products 
For biosynthesis and feeding experiments, cultures were sampled at various timepoints 
by removing a sample of the culture (1 mL), pelleting the cells, and storing the 
supernatant at -20 °C. Samples were later thawed at room temperature, acidific with 1N 
hydrochloric acid (50 µL) and extracted twice with ethyl acetate (2 mL). The ethyl acetate 
fraction was dried to completion and resuspended in methanol (100 µL). For the 
detection and quantification of pathway intermediates, samples were separated on a 
Zorbax SB-C18 column (5 uM, 4.6 X 150 mm) on an Agilent 1100 Series system. A flow 
rate of 1 mL/min according was used according to the following timetable: 5 min at 10% 
methanol, a gradient to 50% methanol for 20 min, and 10 min post-run at 10% methanol. 
For the detection and quantification of HCEs, samples were separated on a Zorbax SB-
C18 column (5 uM, 4.6 X 250 mm) at a flow rate of 1 mL/min according the following 
timetable: 5 min at 45% methanol, a gradient to 55% methanol for 10 min, and 5 min 
post-run at 45% methanol. All buffers contained trifluoroacetic acid (0.1 % v/v). RA 7, IA 
8 and caffeic acid 6 were detected at 330 nm; 4-HPL 2 and 3,4-DHPL 3 were detected at 
223nm; p-coumaric acid 5 was detected at 310 nm. The identities and quantities of all 
intermediates and products except IA 8 were verified by the comparison of retention 
times and UV spectra to authentic standards. Because IA 8 is not commercially 
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available, and due to the similarity of the UV spectra of IA 8 and RA 7 (Figure 3.S2), IA 8 
was quantified using the RA 7 standard curve. For LC-MS analysis of HCEs, the HPLC 
method was transferred to a Thermo Finnigan Spectra System HPLC in line with a 
Thermo Finnigan LCQ ion trap. The same HPLC method was used as the one listed for 
HCE detection above, except that for elution the trifluoroacetic acid was replaced with 
glacial acetic acid (0.1 % v/v). Negative-mode ESI was used for ionization, and ms/ms 
scanning events were set up for parent ion masses for RA 7 (359.2 ± 2 m/z) and the 
mass of dehydroxylated RA 7 (343.2 ± 2 m/z) using 30% ionization energy for 
fragmentation. 
5. Supporting Information 
Table 3.S1.  Product profile of HCE biosynthesis in cultures supplemented with 
pathway precursors.  Measurements made were taken 48 h after induction of 4CL2 
and cbRAS and supplementation. Values reported are mean ± 95% confidence intervals; 
t-tests were carried out for two-tailed distributions assuming unequal variance. 
 
supplement(s) 
added (1 mM) 
HCE production p-value vs. 
none [RA] / µM [IA] / µM IA : RA 
none 0.14 ± 0.05 0.67 ± 0.01 5.0 ± 1.5 - 
L-tyrosine 0.76 ± 0.04 3.0 ± 0.2 4.0 ± 0.2 0.33 
p-coumaric acid 1.4 ± 0.2 4.2 ± 1.3 3.0 ± 0.5 0.11 
caffeic acid 1.2 ± 0.2 5.5 ± 0.3 4.8 ± 0.5 0.81 
caffeic acid 
and 4-HPL 
3.6 ± 0.9 170 ± 50 48 ± 3 0.0002 
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Table 3.S2. Product profile of HCE biosynthesis in cells expressing three RAS 
orthologs 72 h after RAS and at4CL2 induction.  Values reported are mean ± 95% 
confidence intervals; t-tests were carried out for two-tailed distributions assuming 
unequal variance. 
 
 
HCE production p-value vs. 
[RA] / µM [IA] / µM IA : RA CbRAS LaRAS MoRAS 
CbRAS 0.3 ± 0.1 1.1 ± 0.1 3.3 ± 0.5 -   
CaRAS 0.9 ± 0.2 3.2 ± 0.5 3.5 ± 0.4 0.64 -  
MoRAS 1.8 ± 0.3 5.2 ± 0.6 2.9 ± 0.6 0.39 0.20 - 
 
Table 3.S3. Strains used in this study. 
Strain Description Source 
Escherichia coli C2566 
fhuA2 lacZ::T7 gene1 [lon] ompT gal sulA11 
R(mcr-73::miniTn10--Tet
S
)2 [dcm] R(zgb-
210::Tn10--Tet
S
) endA1 Δ(mcrC-
mrr)114::IS10 
New England 
Biolabs, Ipswich, 
MA, USA 
Escherichia coli BW27794 
lacIq rrnB3 DlacZ4787 hsdR514 
DE(araBAD)567 DE(rhaBAD)568 
DE(araFGH) U(DaraEp PCP")±araE) 
[119]
 
Lactobacillus delbrueckii 
subsp. bulgaricus  
LMG6901 = NCIB11778; isolated from 
Bulgarian yoghurt 
DSM-20081, 
[159]
 
Saccharothrix espanaensis Type strain DSM-44229, 
[18]
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Table 3.S4. Primers used for gene amplification 
 
Target 
Gene 
Primer RE Site Sequence 
hdhA Forward NdeI 5’ – GGATCCCATATGACTAAAATTGCCATG – 3’ 
 Reverse NotI 5’ – ATATATGCGGCCGCTTACAGGTTAACGATGC – 3’ 
 
Mutagenic 
Forward 
- 5’ – GCAAGATCGGGGAGTTCCGCTACCGTATGG – 3’ 
 
Mutagenic 
Reverse 
- 5’ – CCATACGGTAGCGGAACTCCCCGATCTTGC – 3’ 
rsTAL Forward BglII 5’ – GCCCAGATCTATGCTCGCCATGAGCCCC – 3’ 
 Reverse XhoI  5’ – CTCGAGCTCGAGTCAGACGGGAGATTGC – 3’ 
 
Mutagenic 
Forward 
- 5’ – CCCGCCGGGTTAAATTCCGGCTTCATGG – 3’ 
 
Mutagenic 
Reverse 
- 5’ – CCATGAAGCCGGAATTTAACCCGGCGGG – 3’ 
sam5 Forward BglII 
5’ – 
GCCCAGATCTATGACCATCACGTCACCTGCGCCG – 
3’ 
 Reverse NotI 
5’ – 
AGATCTGCGGCCGCTCAGGTGCCGGGGTTGATCA – 
3’ 
hpaB Forward NdeI 
5’ – GAAGGAGGAGATCTGGATCCATAT 
GAAACCAGAAGATTTCCGCGCCAGTACCC – 3’ 
 Reverse NsiI  
5’ – GCTCGAGGCGGCCGCCATGGATGC 
ATTTATTTCAGCAGCTTATCCAGCATGTTG – 3’ 
hpaC Forward NdeI 
5’ – GTAGAAGGAGGAGATCTGGATCCA 
TATGATGCAATTAGATGAACAACGCCTGCGC – 3’ 
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 Reverse NsiI  
5’ – GCTCGAGGCGGCCGCCATGGATGCA 
TTTAAATCGCAGCTTCCATTTCCAGCATC – 3’ 
at4CL2 Forward BglII 5’ – GCCCAGATCTATGACGACACAAGATGTG – 3’  
 Forward NdeI 5’ – CATAGGCATATGACGACACAAGATGTG – 3’ 
 Reverse NotI  5’ – AGATGTGCGGCCGCCTAGTTCATTAATC – 3’ 
cbRAS Forward BglII 
5’ – GCCCAGATCTATGAAGATAGAAGTCAAAGACTCG 
– 3’ 
 Forward NdeI 
5’ – CATAGGCATATGAAGATAGAAGTCAAAGACTC – 
3’ 
 Reverse NotI 
5’ – AGATATGCGGCCGCTCAAATCTCATAAAACAAC – 
3’ 
 
Table 3.S5. Plasmids used in this study. 
 
Plasmid  Description Source 
Standard Plasmid 
Backbones 
  
pUCBB pMB1 (colE1); Amp
r
 PlacP’ 
[157]
 
pACBB p15A; Cm
r
 PlacP’ 
[157]
 
pCDFBB CloDF13; Strep
r
 PlacP’ 
[157]
 
pUCBB-pBAD pMB1 (colE1); Amp
r
 ParaBAD 
[157]
 
pUCBB-ntH6 
pMB1 (colE1); Amp
r
 PlacP; N-terminal 6xHis-
tag and thrombin cleavage site (ntH6) 
[157]
 
pCR™-Blunt II-TOPO® pMB1 (colE1); Kan
r
 Plac 
Life 
Technologies, 
Carlsbad, CA, 
USA 
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Partial Pathway Plasmids   
pUCBB-rsTAL pUCBB:: PlacP’rsTAL This study 
pUCBB-hdhA pUCBB:: PlacP’hdhA This study 
pUCBB-sam5 pUCBB:: PlacP’sam5 This study 
pUCBB-hpaBC pUCBB:: PlacP’hpaB- PlacP’hpaC This study 
pUCBB-at4CL2 pUCBB:: PlacP’at4CL2 This study 
pUCBB-ntH6-at4CL2 pUCBB:: PlacP’ntH6-at4CL2 This study 
pUCBB-pBAD-at4CL2 pUCBB:: ParaBADntH6-at4CL2 This study 
pUCBB-cbRAS pUCBB:: PlacP’cbRAS This study 
pUCBB-ntH6-cbRAS pUCBB:: PlacP’ntH6cbRAS This study 
pUCBB-pBAD-cbRAS pUCBB:: ParaBADntH6-cbRAS This study 
pUCBB-pBAD-laRAS pUCBB:: ParaBADntH6-laRAS This study 
pUCBB-pBAD-moRAS pUCBB:: ParaBADntH6-moRAS This study 
Acceptor Substrate 
Plasmids 
  
pUCBB-ABCR 
pUCBB:: PlacP’hdhA-PlacP’hpaB- PlacP’hpaC-P 
lacP’ntH6-cbRAS 
This study 
pUCBB-ABC pUCBB:: PlacP’hdhA-PlacP’hpaB- PlacP’hpaC This study 
Donor Substrate Plasmids   
pCDFBB-TBC4 
pCDFBB:: PlacP’rsTAL- PlacP’hdhA-
PlacP’hpaB- PlacP’hpaC-ParaBADntH6-at4CL2 
This study 
pACBB-TBC4 
pACBB:: PlacP’rsTAL- PlacP’hdhA-PlacP’hpaB- 
PlacP’hpaC-ParaBADntH6-at4CL2 
This study 
pCDFBB-TBC 
pCDFBB:: PlacP’rsTAL- PlacP’hdhA-
PlacP’hpaB- PlacP’hpaC 
This study 
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Hydroxycinnamoyl Transfer 
Plasmids 
  
pACBB-4cbR 
pACBB::ParaBADntH6-at4CL2-ParaBADntH6-
cbRAS 
This study 
pACBB-4laR 
pACBB::ParaBADntH6-at4CL2-ParaBADntH6-
laRAS 
This study 
pACBB-4moR 
pACBB::ParaBADntH6-at4CL2-ParaBADntH6-
moRAS 
This study 
 
Figure 3.S1.  Simultaneous conversion of p-coumaric acid and 4-HPL to caffeic acid and 
3,4-DHPL, respectively, by E. coli BW27784 transformants of pUCBB-hpaBC.  As in Figure 
3.3, transformants were cultured in minimal media at 30 °C, but were supplemented with both 1 
mM p-coumaric acid 5 and 1 mM 4-HPL 2.   Media samples were taken over time and processed 
for HPLC analysis. Samples were compared to standard compounds in order to identify 
compound peaks. Solid trace, pUCBB-hpaBC transformants; dotted trace, empty pUCBB 
transformants (control).   
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Figure 3.S2.  UV spectra of rosmarinic acid and isorinic acid.  The chromatogram and 
spectrum for the RA 7 standard are shown in blue; the chromatogram and spectra for RA 7 and 
IA 8 produced by E. coli BW27784 cells harboring pUCBB-ABC, pCDFBB-TBC, and pACBB-
4moR 48 h after induction are shown in blue.  Experimental details are as described in the main 
text. 
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Figure 3.S3.  Accumulation of a dark pigment assumed to be melanin in E. coli cells 
expressing hpaBC.  A)  E. coli BW27784 cells harboring either pUCBB (empty) or pUCBB-
hpaBC streaked on LB-agar plates and cultured overnight at 37 °C.  B)  E. coli BW27784 cells 
harboring either pUCBB (empty) or pUCBB-hpaBC grown from a single colony in liquid LB media 
at 37 °C. 
 
 
Figure 3.S4.  Expression of three RAS orthlogs. E. coli BW27784 were co-transformed with 
pUCBB-ABC, pCDFBB-TBC and pACBB-4cbR, pACBB-4laR or pACBB-4moR and cultured in 
100 mL modified M9 media.  After 24 h of induction, cell lysates were subjected to anti-His-tag 
Western blotting to check the relative expression of the three RAS enzymes.  T, total lysate; S, 
soluble fraction.  
 
 93 
 
Figure 3.S5.  Addition of an N-terminal His-tag to At4CL2 and CbRAS for increased 
expression levels. P, pellet; S, soluble fraction. A) No visible expression of at4CL2 and cbRAS 
before addition of an N-terminal His-tag via SDS-PAGE. B) SDS-PAGE of At4CL2 and CbRAS 
after the addition of an N-terminal His-tag shows a visible band for at4CL2 expression in the 
pellet fraction after 24h. C) An anti-His-tag Western blot shows translation of both at4CL2 and 
cbRAS with N-terminal His-tags. 
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Chapter 4. Exploring Engineered Metabolons: Investigation of 
Cargo Encapsulation within Eut Bacterial Microcompartments 
Summary 
Bacterial microcompartments (BMCs) are proteinaceous organelles found in many 
bacterial taxa for the sequestration of metabolic enzymes and volatile or toxic 
intermediates.  Engineered ethanolamine utilization (Eut) BMCs have shown promise as 
a means to encapsulate heterologous biosynthetic pathways in E. coli.  Our group 
recently showed that the co-expression of Eut BMC shell proteins and a protein 
equipped with a signal peptide (EutC1-19) led to protein encapsulation within Eut BMC 
shells.  In this work, I have explored the possibility of localizing heterologous biosynthetic 
pathway enzymes to Eut BMCs in order to alter the pathway’s product profile.  EutC1-19-
tagged eGFP fusions of the enzyme HpaB localized to recombinant Eut shells, while 
tagged fusions of HdhA did not.  In order to probe the protein-protein interactions 
governing enzyme encapsulation within Eut BMCs, we created mutants of EutS, a shell 
protein that is necessary and sufficient for recombinant shell formation and EutC1-19-
mediated encapsulation.  One mutant of the lumenal helix of EutS, EutSL29A, disrupted 
EutC1-19-eGFP localization to Eut shells, suggesting that a specific interaction exists 
between EutC1-19 and the lumenal helix of EutS.  Ongoing work is underway to identify 
other Eut encapsulation signal peptides and investigate their interactions with EutS and 
other Eut shell proteins. 
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1. Introduction 
Bacterial microcompartments (BMCs) are proteinaceous organelles found in a broad 
range of bacterial taxa.[71, 168]  The compartments consist of polyhedral selectively-
permeable protein shells which are made up of lattices of proteins with a conserved 
BMC domain (PF00936).[90]  Metabolic enzymes are encapsulated within the shell, often 
encoded within a single operon in the bacterial genome.[169]  In nature, BMCs limit the 
diffusion of metabolic intermediates, which serves to increase the efficiency of metabolic 
pathways and/or protect the cell from toxic intermediates. The first BMCs discovered 
were the carboxysomes in cyanobacteria, which sequester the enzymes carbonic 
anhydrase and RuBisCo, increasing the local concentration of CO2 relative to RuBisCo 
as well as excluding O2 and preventing the oxygenase reaction of RuBisCo.
[170-171]  More 
recently, BMCs involved in the metabolism of non-standard carbon sources – referred to 
as metabolons – have been characterized.  The two best-studied examples are the 1,2-
propanediol utilization (Pdu) and ethanolaimine utilization (Eut) BMCs, which serve to 
sequester propionaldehyde and acetaldehyde, respectively, which would otherwise be 
toxic to the cell.[90, 172-174]  The components of both the Eut and Pdu BMCs are encoded 
by operons containing open reading frames for multiple BMC-domain proteins and 
metabolic enzymes.[175-176] 
 The ability to selectively sequester enzymes and volatile or toxic intermediates in 
a sub-cellular compartment would have a number of valuable applications in 
biotechnology.  Multiple enzymes in a biocatalytic pathway could be localized to a BMC 
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and the BMC purified, creating a one-step means of supplying a “package” of catalytic 
enzymes for in vitro biocatalysis.  Alternatively, key enzymes in a heterologous in vivo 
biosynthetic pathway could be localized to engineered BMCs to limit the diffusion of 
certain intermediates.  As a first step towards developing a system for the engineering of 
BMCs, Choudhary et al. showed that heterologously expressing the five shell proteins of 
the Eut operon from Salmonella enterica LT2 (EutSMNLK) in Escherichia coli led to the 
formation of heterologous BMC shells.[87]  Interestingly, EutS expressed alone also led to 
the formation of BMC shells in E. coli, while the rest of the shell proteins expressed 
alone did not.  Additionally, Choudhary et al. discovered that an N-terminal signal 
peptide from EutC, a subunit of the ethanolamine ammonia lyase encapsulated in native 
Eut BMCs, led to the localization of fluorescent markers and other enzymes into the 
interior of both EutS-only recombinant shells and EutSMNLK recombinant shells.[87]  
While other groups have achieved the formation of empty BMC shells in E. coli using the 
Pdu operon from Citrobacter freundii[85] and the carboxysome CsoS operon from 
Halothiabacillus neapolitanus[86], these systems required the expression of at least five 
shell proteins for shell formation.  Furthermore, while N-terminal targeting peptides have 
been shown to allow cargo protein localization within native Pdu BMCs,[88-89] to our 
knowledge these signal peptides have not been utilized in conjunction with recombinant 
Pdu shells. 
 In order to fully utilize the recombinant Eut BMC system for biocatalytic 
applications, we need to understand the mechanism and dynamics of encapsulation of 
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cargo proteins within the recombinant shells.  While Choudhary et al. showed that the 
signal peptide EutC1-19 is sufficient to encapsulate cargo proteins within the shell, no one 
has yet demonstrated the encapsulation of non-native metabolic enzymes to 
recombinant BMCs.[87]  Additionally, native Eut compartments contain at least six 
enzyme components for the metabolism of ethanolamine, suggesting the presence of 
functional signal peptides on the N-termini of other Eut cargo proteins.[177]  The 
identification of additional functional signal peptides could allow more precise control 
over the stoichiometry of enzymes localized to heterologous BMCs.  Furthermore, an 
understanding of the protein-protein interactions governing cargo protein encapsulation 
is critical to the tuning of engineered BMCs.  In this work, we explore these aspects of 
recombinant Eut BMCs in order to build their utility for in vitro biocatalysis and metabolic 
engineering. 
2. Results and Discussion 
2.1 Exploring the encapsulation of key enzymes to improve a rosmarinic acid 
biosynthetic pathway 
One potential use of engineered Eut BMCs is the encapsulation of enzymes in a 
recombinant biosynthetic pathway to limit the diffusion of certain metabolic 
intermediates.  This could be of particular use in the novel rosmarinic acid (RA) 
biosynthetic pathway constructed in Chapter 3.  The final enzyme in the pathway, 
rosmarinic acid synthase (RAS) accepts both 3,4-dihydroxyphenyllactate (3,4-DHPL) 
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and 4-hydroxyphenyllactate (4-HPL) as substrates, leading to the biosynthesis of both 
RA and the side product isorinic acid (IA), respectively.  While RA has value as an 
antioxidant and potentially a pharmaceutical (reviewed in [23, 46]), the value of IA as a 
bioactive compound is unknown.  However, in the engineered RA biosynthetic pathway, 
IA is the favored product, resulting in a ~4:1 ratio of IA to RA produced (Figure 3.6).  One 
approach to decreasing the production of IA and altering the product profile to favor RA 
biosynthesis would be to decrease the concentration of 4-HPL available to RAS.   
 We propose that localization of part of the RA biosynthetic pathway – specifically, 
the enzymes responsible for the conversion of 4-hydroxyphenylpyruvate (4-HPP) to 3,4-
DHPL (HdhA and the HpaBC complex) – to the interior of a BMC would limit the diffusion 
of 4-HPL in the cytosol and thus decrease the availability of 4-HPL to cytosolic 3,4-DHPL 
(Scheme 4.1).  Because little is understood about the selective permeability of Eut 
BMCs,[177] we cannot assume that it will be permeable to 3,4-DHPL but impermeable to 
4-HPL; rather, we hypothesize that the rate of conversion of 4-HPL to 3,4-DHPL will be 
greater than the rate of 4-HPL diffusion out of the membrane, thus decreasing the 
cytosolic concentration of 4-HPL.  Stochastic simulation of encapsulation of biosynthetic 
pathways has predicted an increase in pathway flux based on the assumption of general 
diffusion limitation.[178]  To test this hypothesis, we are working to assemble a simplified 
version of the RA biosynthetic pathway, where 4-HPP and caffeic acid will be fed to cells 
and At4CL2 will be expressed in the cytoplasm, while HdhA and HpaB will be expressed 
with the N-terminal EutC1-19 signal sequence for localization to the BMC interior (Scheme 
 99 
 
4.1).  HpaC may be localized to the BMC interior through protein-protein interaction with 
HpaB; alternatively, an HpaBC protein fusion could be created for the localization of the 
HpaBC complex to the BMC. 
 
 In order to determine the feasibility of this model, we constructed EutC1-19-tagged 
eGFP fusions of HdhA and HpaB and assessed the encapsulation of these proteins in 
 
Scheme 4.1. Proposed model of a partially-sequestered RA biosynthetic pathway.  The 
EutC
1-19
 signal sequence will be used to target HdhA and HpaBC to a recombinant Eut BMC; 
meanwhile, un-tagged RAS and At4CL2 will be expressed in the cytosol.  If the rate of 
conversion of 4-HPL to 3,4-DHPL is greater than the rate of 4-HPL diffusion out of the BMC 
shell, then the pathway with BMC-localized HdhA and HpaBC will lead to a decreased 
cytosolic 4-HPL concentration compared with a completely cytosolic pathway.  This, in turn, 
would result in an increase in the ratio of RA to IA in the pathway product profile.   4-HPP, 4-
hydroxyphenylpyruvate; 4-HPL,4- hydroxyphenyllactate; 3,4-DHPL, 3,4-
dihydroxyphenyllactate.  For an explanation of enzyme names and functions, see Chapter 3. 
 100 
 
recombinant Eut BMC shells.  These fusions were designed to contain the EutC1-19 
signal sequence, the enzyme, and a C-terminal fusion of eGFP, with flexible (Gly-Ser)6-
Gly linkers separating the open reading frame (ORF) of the enzyme from both the signal 
peptide and the eGFP reporter (Figure 4.1).  These fusions were cloned into pACBB 
under the control of a constitutive lac promoter to give the plasmids pACBB-EutC1-19-
HdhA-eGFP and pACBB-EutC1-19-HpaB-eGFP.  E. coli BW27784 cells were 
cotransformed with one of these fusion constructs or pACBB-EutC1-19-eGFP and a Eut 
shell protein plasmid, either empty pUCBB, pUCBB-EutS, or pUCBB-EutSMNLK; 
transformants were cultured in minimal media overnight at 30 °C and observed via 
fluorescence microscopy.  When expressed in the absence of recombinant Eut shells, 
EutC1-19-HpaB-eGFP is diffuse throughout the cells, while EutC1-19-HdhA-eGFP shows 
polar aggregation in some cells (Figure 4.2).  When coexpressed with EutS alone, EutC1-
19-HdhA-eGFP continues to show fluorescent foci that resemble polar aggregation and 
are distinct from the slightly-off-center localization pattern of EutC1-19-eGFP; EutC1-19-
HpaB-eGFP is still diffuse throughout the cells (Figure 4.3).  Finally, when coexpressed 
with EutSMNLK, EutC1-19-HdhA-eGFP continues to show signs of polar aggregation, 
while EutC1-19-HpaB-eGFP forms loci resembling the localization pattern of EutC1-19-
eGFP (Figure 4.4).  These results suggest that it may be feasible to localize EutC1-19-
tagged HpaB to recombinant  
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EutSMNLK shells; however, the expression of the HdhA fusion would need to be tuned 
to better understand whether it can be localized to a recombinant BMC or not. 
 If encapsulation of both EutC1-19-HdhA and EutC1-19-HpaB can be achieved 
individually, the next step will be to verify the colocalization of the enzymes to 
recombinant BMC shells.  This can be done by creating enzyme-fluorophore fusions 
using two distinct fluorophores that can localize to the recombinant BMC interior.  After 
several failed attempts to achieve localization of red fluorophore to recombinant BMCs, 
our group has recently achieved the simultaneous colocalization of eGFP and BFP (blue 
fluorescent protein) to recombinant BMCs (data not shown), which would allow the 
detection of colocalization of two enzyme-fluorophore fusions.  Encapsulation of the two 
enzymes would also be verified by BMC purification and analysis via SDS-PAGE and N-
terminal peptide sequencing.  This method could also be used to determine whether the 
protein-protein interaction between HpaB and HpaC is strong enough that EutC1-19-HpaB 
 
Figure 4.1.  Enzyme-eGFP fusion constructs for the visualization of encapsulation into 
recombinant Eut BMCs.  The ORF of each enzyme is separated by a flexible (Gly-Ser)6-Gly 
linker (grey) from the signal peptide (purple) and the eGFP ORF.  The fusions are expressed 
constitutively from a modified lac promoter. 
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Figure 4.2.  Expression of EutC1-19-tagged enzyme-eGFP fusions in the absence of 
shell proteins.  E. coli BW27784 cells were transformed with pACBB-EutC
1-19
-eGFP, 
pACBB-EutC
1-19
-HdhA-eGFP or pACBB-EutC
1-19
-HpaB-eGFP, cultured overnight in minimal 
media, and subjected to fluorescence microscopy.  Expression of EutC
1-19
-eGFP and EutC
1-
19
-HpaB-eGFP appears to be diffuse (top and bottom); some cells expressing EutC
1-19
-HdhA-
eGFP shows some foci near the poles which appear consistent with aggregation (middle). 
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Figure 4.3.  Coexpression of EutC1-19-tagged enzyme-eGFP fusions with EutS.  E. coli 
BW27784 cells were cotransformed with pACBB-EutC
1-19
-eGFP, pACBB-EutC
1-19
-HdhA-
eGFP or pACBB-EutC
1-19
-HpaB-eGFP, cultured overnight in minimal media, and subjected to 
fluorescence microscopy.  Expression of EutC
1-19
-eGFP appears in off-center foci consistent 
with BMC compartmentalization seen in previous work (top); some cells expressing EutC
1-19
-
HdhA-eGFP shows some foci near the poles which appear consistent with aggregation 
(middle); expression of EutC
1-19
-HpaB-eGFP appears to be diffuse (bottom). 
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Figure 4.4.  Coexpression of EutC1-19-tagged enzyme-eGFP fusions with EutSMNLK.  
E. coli BW27784 cells were cotransformed with pACBB-EutC
1-19
-eGFP, pACBB-EutC
1-19
-
HdhA-eGFP or pACBB-EutC
1-19
-HpaB-eGFP, cultured overnight in minimal media, and 
subjected to fluorescence microscopy.  Expression of EutC
1-19
-eGFP and EutC
1-19
-HpaB-
eGFP appears in off-center foci consistent with BMC compartmentalization (top and bottom); 
cells expressing EutC
1-19
-HdhA-eGFP shows foci near the poles consistent with aggregation 
(middle). 
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could “pull” HpaC into the BMCs during encapsulation; if not, a fusion of the HpaB and 
HpaC enzymes could be created to allow the cofactor-recycling complex to be 
encapsulated.  Finally, once HdhA and HpaB are successfully encapsulated in vivo, E. 
coli cells could be transformed with plasmids for the expression EutC1-19-HdhA, EutC1-19-
HpaB, At4CL2 and RAS and coexpressed with or without recombinant shell proteins, 
and the levels of pathway intermediates and products could be measured (Scheme 4.1).  
If HdhA and HpaB localization within a recombinant BMC does limit the diffusion of 4-
HPL, then when the recombinant shell proteins are expressed, we should see a 
decrease in the detectable levels of cytosolic 4-HPL and an increase in the ratio of RA to 
IA production from the pathway. 
 While this work constitutes an important first step towards the encapsulation of 
metabolic pathways within engineered BMCs, this approach currently has several 
pitfalls.  First, it is possible that EutC1-19-tagged HdhA may not localize to the BMCs at 
all, potentially due to poor protein folding with the EutC1-19-tag or interference of HdhA’s 
quaternary structure with encapsulation.  Our repeated failure to localize EutC1-19-tagged 
red fluorescent proteins to recombinant BMCs suggests that some proteins are less 
efficiently encapsulated than others for reasons we do not yet understand, which limits 
the application potential of this system.  Second, it is unclear why EutC1-19-tagged HpaB 
would be encapsulated by EutSMNLK shells, but not EutS-only shells (Figures 4.3 and 
4.4).  This again suggests that encapsulation efficiency is dependent not only on the 
presence of the EutC1-19 signal peptide, but also on protein-protein interactions which 
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currently remain uncharacterized.  Finally, because only one signal peptide has been 
identified that can localize proteins to recombinant Eut BMCs, there is no way to fine-
tune the stoichiometry of enzymes encapsulated within a single shell.  Ultimately, in 
order to effectively use recombinant Eut BMCs in biocatalytic applications, we need a 
more thorough understanding of the mechanism of protein encapsulation within Eut 
BMCs. 
2.2 In vivo investigation of the encapsulation mechanism of the EutC1-19 signal 
peptide in recombinant Eut BMCs 
Recently, some light has been shed on the mechanism of cargo protein encapsulation 
with native Pdu-type BMCs.  Fan et al. showed that encapsulation of the cargo protein 
PduP relies on protein-protein interactions of the PduP N-terminal peptide with the 
lumenal helix of the PduA shell protein, and identified key shell and cargo protein 
residues mediating this interaction through site-directed mutagenesis.[179]  They found 
that mutating any of three key residues of PduA’s lumenal helix – H81, V84 and I88 – led 
to the disruption of PduP encapsulation within Pdu compartments and abolished the 
interaction between PduP and PduA, as observed through in vitro His-tag affinity bait-
and-prey pulldown experiments (Figure 4.5A). They also identified the three residues of 
the helical PduP signal peptide involved in this interaction – E7, I10, and L14 – through 
similar experimentation.[179]  The authors suggest that this interaction study provides 
evidence for a “cognate pair” model of cargo protein encapsulation within BMCs, in 
which certain cargo-shell pairs specifically interact to mediate encapsulation. 
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Figure 4.5.  Structure of the lumenal helix of BMC shell proteins involved in cargo 
protein encapsulation.  The shell protein lumenal helices are shown in magenta, and 
residues shown to be involved in cargo protein encapsulation are shown as stick structures 
and labeled.  A, structure of PduA, with encapsulation residues implicated by Fan et al.;
[177] 
B, structure of EutS, showing L29 residue involved in EutC
1-19
-tagged protein encapsulation; 
C, half of a EutS hexamer, showing little space for interaction of the EutC
1-19
 signal peptide. 
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 While the cognate pair model of encapsulation within BMCs is compelling, direct 
evidence of the model – i.e. demonstrated specific interaction of another cognate shell-
cargo protein pair – has not been published, and bioinformatic analysis offers an 
alternative model for encapsulation.  We observed that the N-termini of multiple Pdu and 
Eut cargo proteins, including EutC, exhibit the same pattern as the PduP signal peptide, 
with a ExxOxx(x)O motif, where O is a hydrophobic residue (Figure 4.6).  These 
conserved residues are consistent with a negative-hydrophobic-hydrophobic pattern on 
one side of an α-helix, which could interact with a positive-hydrophobic-hydrophobic 
pattern on one side of a shell protein lumenal helix, as is the case with PduA (Figure 
4.5).  This suggests the possibility of a more degenerate mechanism of cargo protein 
encapsulation, in which a number of cargo signal peptides could interact with a number 
of shell lumenal helices for the encapsulation of multiple proteins simultaneously. 
 
 
Figure 4.6. Multiple sequence alignment of the N-termini of several Eut and Pdu cargo 
proteins.  Alignment was performed using ClustalW2.  Residues of the putative conserved 
ExxOxx(x)O motif are indicated with arrows.   
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Figure 4.7A.  Alanine scanning of EutS lumenal helix to determine key residues in 
EutC1-19-tagged protein encapsulation. E. coli C2566 cells were cotransformed with 
pACBB-EutC
1-19
-eGFP and a plasmid expressing the indicated EutS mutants from a pUCBB 
backbone.  Cells were cultured overnight at 30 °C and subjected to fluorescence microscopy.  
All mutants in this panel exhibit foci consistent with encapsulation inside EutS shells. 
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 In order to better understand the mechanism of cargo protein encapsulation in 
Eut BMCs, we decided to investigate the protein-protein interactions mediating protein 
encapsulation within recombinant Eut BMCs.  So far, we had identified only one viable 
encapsulation signal peptide, EutC1-19, and we presume that it interacts with the shell 
protein EutS, since it can target proteins to shells composed entirely of EutS (Section 
2.1, Figure 4.2).  First, to determine whether the lumenal helix of Eut S mediates 
localization of EutC1-19-tagged proteins in a manner analogous to the PduA-PduP 
interaction, we performed alanine scanning of all of the residues on the lumenal helix of 
EutS and tested the effect of each mutation on encapsulation of EutC1-19-eGFP into 
EutS-only shells via fluorescence microscopy.  Unlike the PduA-PduP interaction, in 
which three residues were found to be necessary for interaction (Figure 4.5A), only two 
of the EutS residues screened led to abolishment of EutC1-19-eGFP encapsulation 
(Figure 4.7).  While one of these non-encapsulating mutants, EutSL29A, is consistent with 
the key encapsulation residues identified on the PduA lumenal helix, the mutant EutSK32A 
does not fit the positive-hydrophobic-hydrophobic pattern exhibited by PduA (Figure 
4.5A and B).  These data suggest that, while the lumenal helix of EutS is important for 
EutC1-19-mediated encapsulation within EutS shells, the encapsulation mechanism is 
defined by a set of protein-protein interactions distinct from those described for PduA 
and PduP.  
 In addition to understanding the EutS-EutC1-19 interaction, we wanted to probe 
the validity of the cognate pair and degenerate models of protein encapsulation within 
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Figure 4.7B.  Alanine scanning of EutS lumenal helix to determine key residues in 
EutC1-19-tagged protein encapsulation. E. coli C2566 cells were cotransformed with 
pACBB-EutC
1-19
-eGFP and a plasmid expressing the indicated EutS mutants from a pUCBB 
backbone.  Cells were cultured overnight at 30 °C and subjected to fluorescence microscopy.  
Mutants EutSL29A and EutSK32A exhibit diffuse fluorescence, indicating a disruption to EutC
1-
19
-eGFP encapsulation. 
 112 
 
Eut shells.  As a first step, we investigated whether the EutC1-19 signal peptide could 
target proteins for encapsulation via interactions with other shell proteins besides EutS, 
as predicted by the degenerate model, or whether it interacts exclusively with EutS, as 
predicted by the cognate pair model.  Because EutS is the only shell protein which forms 
BMCs when expressed alone, we are unable to test the localization of EutC1-19-tagged 
proteins to each shell protein individually.  However, by coexpressing one of the non-
encapsulating EutS mutants with other shell proteins, we can look for EutC1-19-tagged 
protein encapsulation mediated by any of the other four shell proteins.  First, to confirm 
that EutSL29A and EutSK32A are still able to form shells with other shell proteins, we 
coexpressed them with an mCherry-tagged version of EutM, which exhibit red 
fluorescent foci indicating incorporation into BMC shells when coexpressed with wild 
type EutS (Figure 4.8).  While mCherry-EutM coexpressed with EutSL29A forms 
fluorescent foci similar to wild type, coexpression with EutSK32A led to diffuse 
fluorescence, indicating that EutSK32A is unable to form BMC shells with other shell 
proteins and suggesting that the K32A mutation affects encapsulation in EutS only shell 
indirectly by disrupting EutS hexamer formation.   Next, we coexpressed EutSL29A with 
EutM alone, and saw that these compartments were unable to encapsulate EutC1-19-
eGFP, indicating that EutM is not involved in EutC1-19-mediated cargo protein 
encapsulation (Figure 4.9).  Additionally, we coexpressed EutSL29A with the full suite of 
Eut shell proteins – EutMNLK – to determine if any other shell proteins appear to be 
involved in EutC1-19-mediated encapsulation.  We observed no encapsulation of EutC1-19-
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eGFP with EutSL29AMNLK shells, suggesting that EutC
1-19 only interacts with EutS 
(Figure 4.10).  Taken together, these data support the cognate pair model of cargo 
protein encapsulation.  
 
Figure 4.8.  Coexpression of EutS mutants with mCherry-tagged EutM to visualize 
BMC shell formation. E. coli C2566 cells were cotransformed with a plasmid containing the 
indicated EutS mutants and mCherry-EutM on a pACBB backbone.  Cells were cultured 
overnight at 30 °C and subjected to fluorescence microscopy.  mCherry-EutM forms foci 
when expressed with the EutSL29A, indicating shell formation; fluorescence is diffuse with 
SK32A indicating a discruption of shell formation. 
 114 
 
 
 
 While these preliminary results support the cognate pair model, more data are 
needed to establish it as the primary model of cargo protein encapsulation within BMCs.  
First, while we were unable to show binding of the same signal peptide to multiple shell 
proteins, it may be true that multiple signal peptides are able to interact with the same 
shell protein.  In order to investigate this, other signal sequences able to mediate 
encapsulation of cargo to the Eut shells must be identified.  Previously, the ethanol 
 
Figure 4.9.  Coexpression of EutSL29A and EutM shows no evidence of EutM-
mediated encapsulation of EutC1-19-eGFP. E. coli C2566 cells were cotransformed with 
pBBRBB-EutC
1-19
-eGFP and a containing either wild type EutS or EutSL29A and EutM on a 
pACBB backbone.  Cells were cultured overnight at 30 °C and subjected to fluorescence 
microscopy.  Cells expressing EutSL29A exhibit diffuse eGFP fluorescence, indicating no 
encapsulation. 
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dehydrogenase EutG was predicted to have an N-terminal signal peptide for 
encapsulation, based on the presence of an N-terminal extension that is absent in non-
BMC-associated ethanol dehydrogenases.[89]  Our lab has attempted to show 
encapsulation of EutG1-19-tagged proteins to recombinant Eut BMCs, but no localization 
was observed.[87]  It is possible that EutG does have an N-terminal signal peptide, but 
that more than the first 19 residues are required to mediate encapsulation; attempts to 
localize proteins tagged with longer N-terminal extensions of EutG are underway.  
However, based on the presence of a ExxOxx(x)O motif similar to that found in the 
 
Figure 4.10.  Coexpression of EutSL29A and EutMNLK shows no evidence of 
encapsulation of EutC1-19-eGFP mediated by other shell proteins. E. coli C2566 cells 
were cotransformed with pBBRBB-EutC
1-19
-eGFP and a containing either wild type EutS or 
EutSL29A and EutMNLK on a pACBB backbone.  Cells were cultured overnight at 30 °C and 
subjected to fluorescence microscopy.  Cells expressing EutSL29A exhibit diffuse eGFP 
fluorescence, indicating no encapsulation. 
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signal peptide of PduP, the N-terminus of EutE could also potentially be an 
encapsulation signaling peptide for Eut BMCs (Figure 4.6).  If an N-terminal portion of 
EutE is found to mediate the encapsulation of cargo proteins within EutSMNLK shells, 
then further investigation could be done to determine whether the EutE signal peptide 
interacts with EutS or one of the other shell proteins.  If it is found to encapsulate 
enzymes within EutS-only shells, then the interaction of multiple signal sequences with 
the EutS protein would lend credence to the degenerate model of encapsulation.  If it 
does not bind to EutS only shells, but binds to EutSL29AMNLK shells, this would provide 
the first solid basis for the cognate pair model by suggesting that the EutE signal 
sequence forms a cognate pair with a second shell protein. 
 Another way to examine the validity of these models would be via in vitro studies 
of protein-protein interactions between Eut shell and cargo proteins.  The development 
of a method for visualizing shell/cargo protein interactions would allow for the exhaustive 
assessment of all potential shell-cargo cognate pairs.  To this end, we have attempted to 
show the in vitro interaction of shell and cargo proteins through His-tag affinity pull-
downs, using EutS and EutC1-19-eGFP as a proof of concept, since we have visualized 
their interaction in vivo via microscopy.  In this method, the His-tagged “bait” protein is 
and bound to Talon affinity resin, after which a cell lysate containing the potential binding 
partner, the “prey,” is incubated with the resin.  An interaction between the bait and prey 
would result in an elution showing proteins via SDS-PAGE.  Initial pull-downs with EutS 
and EutC1-19-eGFP, using C-terminally His-tagged version of each protein as bait, have 
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showed no interaction.  We note that, while we have so far expressed bait and prey in 
separate cell lines, Fan et al. were able to show interactions between PduA and PduP 
via similar pull-down experiments by expressing both bait and prey in the same cell.[179]  
It is also notable that, while the lumenal helix is clearly important in shell-cargo 
interactions that mediate encapsulation (Figure 4.7B), there appears to be little space 
within the hexameric crystal structure of EutS to accommodate the presence of a helical 
signal peptide (Figure 4.5C).  Based on these observations, we hypothesize that the 
protein-protein interactions governing encapsulation are relatively transient, with 
interaction occurring before shell protein hexamer formation, and release of the cargo 
protein into the lumen of the BMC as shell proteins form the lattices of hexamers that 
make up the shell.  If the EutS in cell lysates used in preliminary pull-down experiments 
had already formed shells, this would explain the failure to show interaction between 
EutS and EutC1-19-eGFP.  To circumvent this problem, we are currently developing 
alternative approaches to these pull-downs, including expression of bait and prey in the 
same cell, as well as constitutive expression of EutC1-19-eGFP followed by late induction 
of EutS expression to try and catch the interaction before BMC shell formation can 
happen.  If we can thus establish an in vitro method for looking at shell/cargo protein 
interactions, we will proceed to test the interaction of all possible shell/cargo pairs to 
determine whether cognate pairs exist, or whether a degenerate pattern of interaction is 
seen. 
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3.  Conclusions 
While engineered BMCs show promise for future applications in in vitro biocatalysis and 
metabolic engineering, there is still much to learn about the mechanism of cargo protein 
encapsulation in order to utilize their full potential.  We have shown the localization of a 
fluorescent reporter fused to one key enzyme in an engineered RA biosynthetic pathway 
to the interior of a Eut BMC, yet the localization of a second enzyme was unsuccessful 
and requires further optimization.  In an effort to understand the protein-protein 
interactions governing encapsulation of EutC1-19-tagged proteins, we identified a key 
residue of the lumenal helix of EutS which, when mutated, disrupts the localization of 
EutC1-19-eGFP to the interior of EutS shells.  This allowed us to coexpress other Eut 
shell proteins with the non-encapsulating EutSL29A mutant determine their involvement in 
EutC1-19-mediated encapsulation.  The inability of EutSL29AMNLK shells to encapsulate 
EutC1-19-eGFP suggests that EutS alone interacts with the EutC1-19 signal peptide, 
providing circumstantial evidence in support of a shell/cargo cognate pair model of 
encapsulation.  To provide further evidence supporting or dismissing this model, we are 
working to identify alternative Eut cargo protein signal sequences, as well as to develop 
a means to detect in vitro protein-protein interactions between all possible shell/cargo 
cognate pairs in the suite of Eut BMC proteins.  This work will provide not only a better 
understanding of cargo protein encapsulation within Eut BMCs but will contribute to the 
set of tools available for recombinant Eut BMC engineering. 
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4. Materials and Methods 
4.1 Materials, Strains and Growth Conditions 
Restriction enzymes, T4 DNA ligase, and Phusion® High Fidelity DNA Polymerase (New 
England Biolabs, Ipswich, MA, USA) were used for the creation of the EutC1-19-tagged 
enzyme-eGFP fusions, as well as building co-expression plasmids of the EutS mutants 
with other shell proteins.  A QuikChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA, USA) was used for site-directed mutagenesis of EutS.  
Glass coverslips (22x22mm, 1.5 thickness, Corning Inc., Tewksbury, MA, USA) and 
BacLightTM mounting oil (Life Technologies, Grand Island, NY, USA) were used in light 
microscopy for encapsulation studies.  Protein structure images were prepared using 
PyMol (Schrodinger, www.pymol.org), and multiple sequence alignment was carried out 
using ClustalW2.1 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
 E. coli C2566 (New England Biolabs, Ipswich, MA, USA) was used for all DNA 
propagation and manipulation, as well as all encapsulation studies of EutS lumenal helix 
mutants (section 2.2).  E. coli BW27784 (E. coli Genetic Stock Center, New Haven, CT) 
[119] was used for localization studies with the EutC1-19-tagged enzyme-eGFP fusions, 
since this was the strain used for the construction of the RA biosynthetic pathway 
(Chaper 3).  Cultures for DNA manipulation were grown at 37 °C in Luria-Burtani (LB) 
medium with the appropriate antibiotics: ampicillin (100 µg/mL), chloramphenicol (50 
µg/mL), and/or kanamycin (30 µg/mL).  For encapsulation experiments, single colonies 
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of transformants containing plasmids for Eut shell expression and a EutC1-19-tagged 
fluorescent reporter were cultured in LB medium at 37 °C for six to eight hours; then, 
these seed colonies were used to inoculate fresh LB cultures to a 1:1000 dilution factor.  
These cultures were incubated with shaking at 30 °C for 15 h before mounting and 
microscopy. 
4.2 Construction of Plasmids 
The EutC1-19-tagged enzyme-eGFP fusions were created using the plasmid pACBB-
EutC1-19-GS-MCS-GS-eGFP, which contains a modified, constitutive lac promoter (PlacP’) 
and ribosome binding site followed by the EutC1-19 signal peptide, a (Gly-Ser)6Gly linker, 
a multiple cloning site, a second (Gly-Ser)6Gly linker, and the ORF for eGFP.  The ORFs 
of hdhA and hpaB were amplified from the plasmids pUCBB-hdhA and pUCBB-hpaB 
(Table 3.S5) using forward primers with a HindIII site at the 5’ end and a reverse primer 
with a KpnI site at the 5’ end.  The resulting PCR products were digested with HindIII 
and KpnI and ligated into pACBB-EutC1-19-GS-MCS-GS-eGFP which had been digested 
with the same enzymes, resulting in the plasmids into pACBB-EutC1-19-HdhA-eGFP and 
pACBB-EutC1-19-HpaB-eGFP. 
 Alanine scanning of the lumenal helix of EutS was carried out via site-directed 
mutagenesis by site directed mutagenesis, using the plasmid pUCBB-EutS as a 
template[87].  All codons for residues from Gly26 to Ile33 were altered to code for Ala, 
except residue Ala30, which was not mutated.  The resulting pUCBB-EutS* mutant 
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plasmids were used for initial studies of EutC1-19 encapsulation (Figure 4.7).  For 
coexpression of the the EutS mutants with mCherry-EutM, wildtype EutM or EutMNLK 
on the same plasmid, the EutS mutants were inserted into pUCBB-mCherry-EutM, 
pUCBB-EutM or pUCBB-EutMNLK through BioBrick™ prefix stacking, as described for 
our group’s customized set of BioBrick™ plasmids.[87, 157]  Briefly, the pUCBB-EutS* 
plasmids were digested with EcoRI and SpeI.  The resulting DNA fragement, containing 
the PlacP’ promoter, ribosome binding site and EutS* ORF was then ligated into the 
pACBB destination plasmids that had been digested with EcoRI and XbaI.  Because 
XbaI and SpeI are isoschizomers, the ligation results in neither an XbaI or EcoRI site 
being restored at ligation point.  This resulted in the plasmids pUCBB-EutS*-mCherry-
EutM, pUCBB-EutS*-EutM or pUCBB-EutS*MNLK.  Finally, these plasmids were all 
digested with EcoRI and SpeI, and the resulting BioBricks containing multiple gene-
encoding sequences were ligated into a pACBB backbone that had been digested with 
the same enzymes, giving pACBB-EutS*-mCherry-EutM, pACBB-EutS*-EutM or 
pACBB-EutS*MNLK.  All plasmids used in this study are listed in Table 4.1. 
4.3 Light Microscopy 
To visualize cargo protein encapsulation within recombinant Eut BMCs, E. coli 
cells were cultured as described in section 4.1, diluted 10:1 in phosphate-buffered saline 
and then mounted onto glass coverslips.  Cells were observed using a Nikon TiE 
microscope with a Lumencor SpectraX light source at 470nm through a Plan Apo 100x, 
1.45n.a objective, and images were collected with an Andor Zyla camera controlled via 
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the Nikon Elements 4.6 software. All instruments are housed and maintained by the 
University of Minnesota – University Imaging Centers, http://uic.umn.edu.  Post-capture 
alignment, false-coloring and cropping was conducted in ImageJ, Fiji and Nikon NIS 
Elements 4.6. 
Table 4.1. Plasmids used in this study. 
 
Plasmid  Description Source 
Standard Plasmid 
Backbones 
  
pUCBB pMB1 (colE1); Amp
r
 PlacP’ 
[157]
 
pACBB p15A; Cm
r
 PlacP’ 
[157]
 
pBBRBB RK2; Kan
r
 PlacP’ 
[157]
 
Enzyme-eGFP Fusion 
Plasmids 
  
pACBB-EutC
1-19
-GS-MCS-
GS-eGFP 
pACBB:: PlacP’ eutC
1-19
 tag-(GS)6G-EcoRV-
HindIII-Acc65I-KpnI-SalI-(GS)-eGFP 
E. Schmidt 
laboratory stock 
pACBB-EutC
1-19
-HdhA-
eGFP 
pACBB:: PlacP’eutC
1-19
-(GS)6G-hdhA-
(GS)6G-eGFP 
This study 
pACBB-EutC
1-19
-HpaB-
eGFP 
pACBB:: PlacP’eutC
1-19
-(GS)6G-hpaB-
(GS)6G-eGFP 
This study 
EutS Plasmids   
pUCBB-EutS pUCBB:: PlacP’eutS 
[87]
 
pUCBB-EutSG26A pUCBB:: PlacP’eutSG26A This study 
pUCBB-EutSE27A pUCBB:: PlacP’eutSE27A This study 
pUCBB-EutSE28A pUCBB:: PlacP’eutSE28A This study 
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pUCBB-EutSL29A pUCBB:: PlacP’eutSL29A This study 
pUCBB-EutSK31A pUCBB:: PlacP’eutSK31A This study 
pUCBB-EutSK32A pUCBB:: PlacP’eutSK32A This study 
Encapsulation Study 
Plasmids 
  
pACBB-EutC
1-19
-eGFP pACBB:: PlacP’eutC
1-
19-eGFP 
[87]
 
pBBRBB-EutC
1-19
-eGFP pBBRBB:: PlacP’eutC
1-
19-eGFP 
[87]
 
pACBB- mCherry-EutM pACBB:: PlacP’mCherry-eutM 
M.A. Held 
laboratory stock 
pACBB- EutS-mCherry-
EutM 
pACBB:: PlacP’eutS-PlacP’mCherry-eutM This study 
pACBB- EutSL29A-mCherry-
EutM 
pACBB:: PlacP’eutSL29A-PlacP’mCherry-eutM This study 
pACBB- EutSK32A-mCherry-
EutM 
pACBB:: PlacP’eutSK32A-PlacP’mCherry-eutM This study 
pUCBB-EutM pUCBB:: PlacP’eutM 
[87]
 
pACBB- EutSM pACBB:: PlacP’eutS-PlacP’eutM This study 
pACBB- EutSL29AM pACBB:: PlacP’eutSL29A-PlacP’eutM This study 
pUCBB-EutMNLK pUCBB:: PlacP’eutMN-PlacP’eutLK 
[87]
 
pACBB- EutSMNLK pACBB:: PlacP’eutS-PlacP’eutMN-PlacP’eutLK 
M.A. Held 
laboratory stock 
pACBB- EutSL29AMNLK pACBB:: PlacP’eutS-PlacP’eutMN-PlacP’eutLK This study 
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Chapter 5. Concluding Remarks  
As the importance of plant natural products in pharmaceutical discovery has become 
more apparent, the need for microbial production platforms becomes more dire.  The last 
two decades have seen the development of a number of valuable tools for the 
biosynthesis of medicinally-relevant plant compounds, including the flavonoid class of 
phenylpropanoid compounds.  However, production of much of the range of plant 
phenylpropanoid classes, including many important pharmaceuticals, has yet to be 
reached with this technology.  My thesis work aimed to expand the capabilities of 
microbial biosynthesis of medicinal plant phenylpropanoids by exploring and developing 
new biosynthetic pathways and metabolic engineering tools in E. coli.  I worked toward 
engineering the biosynthesis of ligans and hydroxycinnamic acid esters, whose de novo 
biosynthesis in E. coli had not yet been achieved.  I have also begun an investigation of 
the utility of engineered bacterial microcompartments (BMCs) as a means of controlling 
spatial organization in metabolic pathway engineering.  This work has contributed 
significantly to our understanding of the capabilities and limitations of existing technology 
for microbial biosynthesis and has expanded the accessible range of phenylpropanoid 
products that can be produced in E. coli. 
 When we began exploring the possibility of engineering lignan biosynthesis in E. 
coli, very little was understood about the mechanism of regio- and stereo-controlled 
oxidative radical coupling.  I was able to achieve random oxidative radical coupling of 
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coniferyl alcohol in E. coli through overexpression of a bacterial laccase, showing that 
this could be a feasible candidate for an oxidase in bacterial lignan production.  
Additionally, I was able to achieve the soluble expression of the characterized dirigent 
protein FiDRP1 in E. coli, which turned out to be a very difficult protein based on my 
experience and later work from other groups.[117]  However, my difficulty in expressing 
FiDRP1 and my inability to show its function in E. coli proved to be a significant obstacle.  
Later publications by other groups showed the necessity of post-translational 
modifications in not only dirigent protein function but also folding and stability, illustrating 
the infeasibility of using E. coli as a host for lignan biosynthesis.[102]  Despite these 
setbacks and the ultimate decision to retire this project, this work has helped provide 
important information for future attempts at lignan biosynthesis in microbes by 
suggesting that a eukaryotic host may be necessary. 
 In addition to lignan biosynthesis, I chose to pursue a platform for 
hydroxycinnamic acid ester (HCE) biosynthesis in E. coli with a focus on rosmarinic acid 
(RA), a potent antioxidant with potential for anti-cancer and neuroprotective 
applications.[23, 46]  The beginning of this work coincided with a seemingly new interest in 
the de novo biosynthesis of hydroxycinnamic acids in E. coli.[47, 50]  While previous 
groups had achieved production of hydroxycinnamoyl amides from fed precursors in E. 
coli,[52-53] at the beginning of this work, there were no reports of microbial biosynthesis of 
HCEs.  Recognizing the potential difficulty of reconstituting the plant RA biosynthetic 
pathway in E. coli, I was able to use recent studies on bacterial caffeic acid biosynthesis 
 126 
 
to restructure the RA pathway and create a novel biosynthetic route using bacterial and 
plant enzymes.  This approach proved successful, and I was able to show titers of RA 
similar to those shown by Eudes et al. before pathway optimization, who had meanwhile 
published a study of the de novo biosynthesis of hydroxycinnamoyl anthranilates in E. 
coli.[54]  Through probing the engineered pathway for bottlenecks, I was able to propose 
several approaches for future optimization of through boosting precursor availability and 
enzyme engineering.  Additionally, due to my modular design of this biosynthetic 
pathway, this could prove to be a promising production platform not only for RA, but for a 
range of other HCEs and hydroxycinnamoyl amides. 
 Recent work in the Schmidt-Dannert laboratory has shown the potential utility of 
engineered ethanolamine utilization (Eut) BMCs in metabolic engineering applications.[87]  
I saw the potential to use this system to eliminate cross-talk within the redesigned RA 
biosynthetic pathway by sequestering a pathway intermediate, leading me to test the 
ability to localize two heterologous enzymes to Eut BMCs.  Mixed results with the ability 
to localize enzymes to the BMCs using the N-terminal signal peptide EutC1-19 led me to 
investigate the mechanism of cargo protein encapsulation within Eut shells.  Previous 
work from other groups and our own observation suggested two potential models for 
enzyme encapsulation within BMCs: specific interactions between cognate pairs of shell 
and cargo proteins, or general interactions between several signal peptides and shell 
proteins.  Through site-directed mutagenesis of the shell protein EutS, I was able to 
provide evidence that a specific interaction between EutS and EutC1-19 mediates cargo 
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protein encapsulation within recombinant Eut BMCs.  In addition, I have suggested 
ongoing work to expand our understanding of protein localization through the 
identification of other signal peptides and a thorough in vitro investigation of interactions 
between Eut shell and cargo proteins.  This work has laid the foundation to deepen our 
understanding of Eut BMCs and increase their utility in metabolic engineering 
applications. 
 Taken together, the work presented in this thesis represents an exploration of the 
potential of microbial biosynthesis of plant phenylpropanoid natural products.  
Throughout the body of this thesis, I have presented multiple avenues for future 
directions for this research.  For example, there is great potential for a microbial 
biosynthetic platform for lignans in a eukaryotic host such as Pichia pastoris.  
Optimization of RA biosynthesis in my system through increasing L-tyrosine 
biosynthesis, enzyme engineering and/or partial pathway colocalization within a BMC 
could lead to an economically viable microbial production platform.  Finally, a study to 
better understand the protein-protein interactions that govern cargo protein 
encapsulation within BMCs will allow a much greater degree of control in metabolon 
engineering.  In conclusion, my exploration of plant phenylpropanoid biosynthesis in E. 
coli has expanded our capabilities in microbial biosynthetic platforms and laid the 
foundation for further development of metabolic engineering tools. 
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